{"content":"<li class=\"n-box-item date-title\" data-end=\"1576126799\" data-start=\"1576040400\" data-txt=\"Monday, December 23, 2019\">Wednesday, December 11, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3525718\" data-ts=\"1576104488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525718-ge-gains-after-new-analyst-ubs-awards-buy-rating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE gains after new analyst at UBS awards Buy rating</a></h4><ul><li>General Electric (NYSE:<a href='https://seekingalpha.com/symbol/GE' title='General Electric Company'>GE</a>) <font color=\"green\">+1.3%</font> after-hours as a new analyst at UBS assumes coverage of the stock with a <a href=\"https://www.cnbc.com/2019/12/11/ge-shares-rise-after-new-analyst-at-ubs-gives-stock-a-buy-rating-and-predicts-a-big-2020-rebound.html\" target=\"_blank\">Buy rating</a> and a $14 price target vs. the firm's previous Neutral rating and $11.50 target.</li><li>New UBS analyst Markus Mittermaier says GE shares are at a \"positive inflection point\" into 2020 given the company's successful de-levering, \"strong\" estimated earnings growth in 2020 and 2021, and a tripling of free cash flow to $2.3B next year; as a result, he expects the stock's narrative to change from \"significant cash drag to successful transformation.\"</li><li>GE's average <a href=\"https://seekingalpha.com/symbol/GE/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Bullish, while both its <a href=\"https://seekingalpha.com/symbol/GE/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> and <a href=\"https://seekingalpha.com/symbol/GE/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525718\" data-linked=\"GE gains after new analyst at UBS awards Buy rating\" data-tweet=\"$GE - GE gains after new analyst at UBS awards Buy rating https://seekingalpha.com/news/3525718-ge-gains-after-new-analyst-ubs-awards-buy-rating?source=tweet\" data-url=\"https://seekingalpha.com/news/3525718-ge-gains-after-new-analyst-ubs-awards-buy-rating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>99&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525716\" data-ts=\"1576103752\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525716-lulu-amrs-acc-and-ggb-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LULU, AMRS, ACC and GGB among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color=\"green\">+11.7%</font>. <a href='https://seekingalpha.com/symbol/GGB' title='Gerdau S.A.'>GGB</a> <font color=\"green\">+4.9%</font>. <a href='https://seekingalpha.com/symbol/EVBG' title='Everbridge, Inc.'>EVBG</a> <font color=\"green\">+4.3%</font>. <a href='https://seekingalpha.com/symbol/FREQ' title='Frequency Therapeutics, Inc.'>FREQ</a> <font color=\"green\">+2.8%</font>. <a href='https://seekingalpha.com/symbol/ACC' title='American Campus Communities, Inc.'>ACC</a> <font color=\"green\">+1.9%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a> <font color=\"red\">-4.1%</font>. <a href='https://seekingalpha.com/symbol/TWST' title='Twist Bioscience Corporation'>TWST</a> <font color=\"red\">-3.9%</font>. <a href='https://seekingalpha.com/symbol/UXIN' title='Uxin Limited'>UXIN</a> <font color=\"red\">-3.7%</font><a href='https://seekingalpha.com/symbol/MESA' title='Mesa Air Group, Inc.'>MESA</a> <font color=\"red\">-2.7%</font>. <a href='https://seekingalpha.com/symbol/ASMB' title='Assembly Biosciences, Inc.'>ASMB</a> <font color=\"red\">-2.3%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525716\" data-linked=\"LULU, AMRS, ACC and GGB among after hour movers\" data-tweet=\"$AMRS $GGB $EVBG - LULU, AMRS, ACC and GGB among after hour movers https://seekingalpha.com/news/3525716-lulu-amrs-acc-and-ggb-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525716-lulu-amrs-acc-and-ggb-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525695\" data-ts=\"1576101038\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASMB\" target=\"_blank\">ASMB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525695-assembly-biosciences-readies-equity-offering-shares-down-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Assembly Biosciences readies equity offering; shares down 4% after hours</a></h4><ul><li>Assembly Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ASMB' title='Assembly Biosciences, Inc.'>ASMB</a>) launches a <a href=\"https://seekingalpha.com/pr/17725903-assembly-biosciences-announces-proposed-public-offering-of-common-stock\" target=\"_blank\">public offering</a> of common stock. Price, volume and terms have yet to be announced.</li><li>Shares down <font color=\"red\">4%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525695\" data-linked=\"Assembly Biosciences readies equity offering; shares down 4% after hours\" data-tweet=\"$ASMB - Assembly Biosciences readies equity offering; shares down 4% after hours https://seekingalpha.com/news/3525695-assembly-biosciences-readies-equity-offering-shares-down-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3525695-assembly-biosciences-readies-equity-offering-shares-down-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525694\" data-ts=\"1576100697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525694-tonix-pharma-nabs-european-patent-covering-tnxminus-102-sl-shares-up-22-ah\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix Pharma nabs European patent covering TNX-102 SL; shares up 22% AH</a></h4><ul><li>Nano cap Tonix Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) is up <font color=\"green\">22%</font> after hours in reaction to its <a href=\"https://seekingalpha.com/pr/17725917-tonix-pharmaceuticals-announces-new-european-patent-for-composition-and-formulation-of\" target=\"_blank\">receipt</a> of a new composition of matter patent in Europe covering TNX-102 SL.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525694\" data-linked=\"Tonix Pharma nabs European patent covering TNX-102 SL; shares up 22% AH\" data-tweet=\"$TNXP - Tonix Pharma nabs European patent covering TNX-102 SL; shares up 22% AH https://seekingalpha.com/news/3525694-tonix-pharma-nabs-european-patent-covering-tnxminus-102-sl-shares-up-22-ah?source=tweet\" data-url=\"https://seekingalpha.com/news/3525694-tonix-pharma-nabs-european-patent-covering-tnxminus-102-sl-shares-up-22-ah\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525691\" data-ts=\"1576100279\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGEN\" target=\"_blank\">MGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525691-miragen-pivots-on-strategy-to-cut-18-jobs-shares-down-11-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Miragen pivots on strategy, to cut 18 jobs; shares down 11% after hours</a></h4><ul><li>Aimed at delivering key milestones next year, Miragen (NASDAQ:<a href='https://seekingalpha.com/symbol/MGEN' title='Miragen Therapeutics, Inc.'>MGEN</a>) <a href=\"https://seekingalpha.com/pr/17725924-miragen-announces-major-changes-to-company-s-strategy\" target=\"_blank\">announces </a>major changes in its strategy. Key points:</li><li>Enrollment in the Phase 2 SOLAR study of cobomarsen in cutaneous T-cell lymphoma will truncated to 30 subjects instead of 126, enabling a readout of topline data in Q2 2020.</li><li>Expanded use of cobomarsen will be focused on adult T-cell leukemia/lymphoma. Meeting with FDA planned for Q2 2020 to clarify development pathway.</li><li>A collaboration partner for remlarsen could be sought.</li><li>18 positions will be terminated, mostly in R&amp;D and project, general and administrative support.</li><li>EVP of R&amp;D Paul Runbin, M.D. will depart at the end of the month.</li><li>Diana Escolar, M.D. named Chief Medical Officer.</li><li>$20M stock purchase agreement signed with Aspire Capital Fund, LLC.</li><li>Management will host a conference call today at 5:00 pm ET to discuss its plan.</li><li>Shares down <font color=\"red\">11%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525691\" data-linked=\"Miragen pivots on strategy, to cut 18 jobs; shares down 11% after hours\" data-tweet=\"$MGEN - Miragen pivots on strategy, to cut 18 jobs; shares down 11% after hours https://seekingalpha.com/news/3525691-miragen-pivots-on-strategy-to-cut-18-jobs-shares-down-11-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3525691-miragen-pivots-on-strategy-to-cut-18-jobs-shares-down-11-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525688\" data-ts=\"1576100033\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OXM\" target=\"_blank\">OXM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525688-oxford-industriesminus-2-after-guidance-tweak\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oxford Industries -2% after guidance tweak</a></h4><ul> <li>Oxford Industries (NYSE:<a href='https://seekingalpha.com/symbol/OXM' title='Oxford Industries, Inc.'>OXM</a>) falls in AH trading after a slight downward <a href=\"https://seekingalpha.com/pr/17725923-oxford-owner-of-tommy-bahama-lilly-pulitzer-and-southern-tide-announces-fiscal-2019-third\" target=\"_blank\">revision</a> to guidance.</li> <li>The company sees full-year revenue of $1.125B to $1.135B vs. $1.135B to $1.155B prior view and $1.14B consensus. EPS of $4.25 to $4.40 is anticipated vs. $4.36 consensus.</li> <li>\"Our fourth quarter sales to date are tracking a bit behind our previous plan and we have modestly trimmed the top end of our earnings outlook,\" notes CEO Thomas Cubb.</li> <li>\"With our powerful brands and brand messaging, our differentiated product, and the incredible shopping experience delivered both online and in-store by our amazing people, we are confident that we can deliver a solid fourth quarter and continue to build shareholder value over the near and long term,\" he adds.</li> <li>Shares of OXM are <font color=\"red\">down 2.15%</font> premarket to $72.80.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525654-oxford-industries-eps-beats-0_02-beats-on-revenue\" target=\"_blank\">Oxford Industries EPS beats by $0.02, beats on revenue</a> (Dec. 11)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525688\" data-linked=\"Oxford Industries -2% after guidance tweak\" data-tweet=\"$OXM - Oxford Industries -2% after guidance tweak https://seekingalpha.com/news/3525688-oxford-industriesminus-2-after-guidance-tweak?source=tweet\" data-url=\"https://seekingalpha.com/news/3525688-oxford-industriesminus-2-after-guidance-tweak\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525681\" data-ts=\"1576099578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FORM\" target=\"_blank\">FORM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525681-formfactor-raises-q4-earnings-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FormFactor raises Q4 earnings outlook</a></h4><ul><li>FormFactor (NASDAQ:<a href='https://seekingalpha.com/symbol/FORM' title='FormFactor, Inc.'>FORM</a>) <a href=\"https://seekingalpha.com/pr/17725920-formfactor-inc-raises-financial-outlook-for-fourth-quarter-fiscal-2019\" target=\"_blank\">updates</a> its Q4 outlook to $170-178M in revenue and $0.27-0.35 EPS (was: $0.22-0.30; consensus: $0.26.)</li><li>Gross margin is expected between 43% and 46% (was: 42-46%).</li><li>The company cites Foundry and Logic strength and robust demand in the other businesses.</li><li>FORM shares were halted ahead of the news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525681\" data-linked=\"FormFactor raises Q4 earnings outlook\" data-tweet=\"$FORM - FormFactor raises Q4 earnings outlook https://seekingalpha.com/news/3525681-formfactor-raises-q4-earnings-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3525681-formfactor-raises-q4-earnings-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525678\" data-ts=\"1576099368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRD\" target=\"_blank\">TLRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525678-tailored-brandsplus-10-after-earnings-topper\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tailored Brands +10% after earnings topper</a></h4><ul> <li>Tailored Brands (NYSE:<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc.'>TLRD</a>) reports Q3 EPS ahead of even the highest estimate turned in by analysts.</li> <li>Q3 comparable sales by brand: Men's Wearhouse -2.8%, Jos A. Bank +0.5%, K&amp;G -1.5%, Moore's Canada -5.5%.</li> <li>CEO update: \"Our third quarter performance reflects continued progress in each of our transformational strategies, including improved sales in our polished casual categories, higher online sales driven by enhanced e-commerce experiences and online marketing, and new customer acquisition and increased traffic reflecting more effective marketing campaigns and channel strategies.\"</li> <li>Looking ahead, Q3 EPS of -$0.55 to -$0.50 is anticipated vs. -$0.36 consensus.</li>  <li>Shares of TLRD are <font color=\"green\">up 10.31%</font> AH to $5.34.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525667-tailored-brands-eps-beats-0_10-beats-on-revenue\" target=\"_blank\">Tailored Brands EPS beats by $0.10, beats on revenue</a> (Dec. 11)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525678\" data-linked=\"Tailored Brands +10% after earnings topper\" data-tweet=\"$TLRD - Tailored Brands +10% after earnings topper https://seekingalpha.com/news/3525678-tailored-brandsplus-10-after-earnings-topper?source=tweet\" data-url=\"https://seekingalpha.com/news/3525678-tailored-brandsplus-10-after-earnings-topper\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525669\" data-ts=\"1576099146\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKTS\" target=\"_blank\">AKTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525669-akoustis-falls-on-public-offering-plans\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akoustis falls on public offering plans</a></h4><ul><li>Akoustis Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AKTS' title='Akoustis Technologies, Inc.'>AKTS</a>) <a href=\"https://seekingalpha.com/pr/17725929-akoustis-announces-proposed-public-offering-of-common-stock\" target=\"_blank\">announces</a> plans to offer common stock shares in an underwritten public offering.</li><li>AKTS expects to grant the underwriters a 30-day option to purchase additional shares.</li><li>The share amounts weren't disclosed.</li><li>Akoustis will use the proceeds to fund operations and towards business growth.</li><li>AKTS shares are <font color=\"red\">down 6.5%</font> after hours to $7.10.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525669\" data-linked=\"Akoustis falls on public offering plans\" data-tweet=\"$AKTS - Akoustis falls on public offering plans https://seekingalpha.com/news/3525669-akoustis-falls-on-public-offering-plans?source=tweet\" data-url=\"https://seekingalpha.com/news/3525669-akoustis-falls-on-public-offering-plans\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525668\" data-ts=\"1576099081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525668-lululemonminus-4-despite-sizzling-comp-sales-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon -4% despite sizzling comp sales growth</a></h4><ul>  <li>Lululemon (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>) reports comparable sales jumped 16% Y/Y in <a href=\"https://seekingalpha.com/news/3525652-lululemon-athletica-eps-beats-0_03-beats-on-revenue\" target=\"_blank\">Q3</a> to more than double the consensus estimate for a 5.2% gain. Comparable sales were up 17% on a constant dollar basis.</li> <li>Comparable store sales were up 10% and direct-to-consumer revenue was up 29%.</li>  <li>Gross margin came in at 55.1% of sales vs. 54.6% consensus and 54.4% a year ago. Operating margin improved to 19.2% of sales.</li>  <li>Looking ahead, Lululemon anticipates full-year revenue of $3.895B to $3.910B vs. $3.80B to $3.84B prior and $3.89B consensus. EPS of $4.75 to $4.80 is anticipated vs. $4.75 consensus. For Q4, Lululemon sees revenue of $1.315B to $1.330B and EPS of $2.10 to $2.13 vs. $2.13 consensus.</li> <li>Shares of LULU are <font color=\"red\">down 4.41%</font> AH to $223.29 with investors focusing on the guidance over the sizzling comp sales.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525652-lululemon-athletica-eps-beats-0_03-beats-on-revenue\" target=\"_blank\">Lululemon Athletica EPS beats by $0.03, beats on revenue</a> (Dec. 11)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3525668\" data-linked=\"Lululemon -4% despite sizzling comp sales growth\" data-tweet=\"$LULU - Lululemon -4% despite sizzling comp sales growth https://seekingalpha.com/news/3525668-lululemonminus-4-despite-sizzling-comp-sales-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3525668-lululemonminus-4-despite-sizzling-comp-sales-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525667\" data-ts=\"1576099044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRD\" target=\"_blank\">TLRD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525667-tailored-brands-eps-beats-0_10-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tailored Brands EPS beats by $0.10, beats on revenue</a></h4><ul><li>Tailored Brands (NYSE:<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc.'>TLRD</a>): Q3 Non-GAAP EPS of $0.53 <font color=\"green\">beats by $0.10</font>; GAAP EPS of $0.56 <font color=\"green\">beats by $0.13</font>.</li><li>Revenue of $729.48M (-3.0% Y/Y) <font color=\"green\">beats by $14.05M</font>.</li><li>Shares <font color=\"green\">+12.6%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17725938-tailored-brands-inc-reports-fiscal-2019-third-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3525667\" data-linked=\"Tailored Brands EPS beats by $0.10, beats on revenue\" data-tweet=\"$TLRD - Tailored Brands EPS beats by $0.10, beats on revenue https://seekingalpha.com/news/3525667-tailored-brands-eps-beats-0_10-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3525667-tailored-brands-eps-beats-0_10-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525651\" data-ts=\"1576098354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTSV\" target=\"_blank\">FTSV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525651-forty-seven-initiates-140m-equity-offering-shares-down-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Forty Seven initiates $140M equity offering; shares down 4% after hours</a></h4><ul><li>Forty Seven (NASDAQ:<a href='https://seekingalpha.com/symbol/FTSV' title='Forty Seven, Inc.'>FTSV</a>) <a href=\"https://seekingalpha.com/pr/17725883-forty-seven-inc-announces-proposed-underwritten-public-offering-of-common-stock\" target=\"_blank\">launches </a>a $140M public offering of common stock. Price, volume and terms have yet to be announced.</li><li>Shares down <font color=\"red\">4%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525651\" data-linked=\"Forty Seven initiates $140M equity offering; shares down 4% after hours\" data-tweet=\"$FTSV - Forty Seven initiates $140M equity offering; shares down 4% after hours https://seekingalpha.com/news/3525651-forty-seven-initiates-140m-equity-offering-shares-down-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3525651-forty-seven-initiates-140m-equity-offering-shares-down-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525647\" data-ts=\"1576098239\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MESA\" target=\"_blank\">MESA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525647-mesa-air-eps-in-line-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mesa Air EPS in-line, beats on revenue</a></h4><ul><li>Mesa Air (NASDAQ:<a href='https://seekingalpha.com/symbol/MESA' title='Mesa Air Group, Inc.'>MESA</a>): Q4 Non-GAAP EPS of $0.36 in-line; GAAP EPS of $0.35 <font color=\"red\">misses by $0.01</font>.</li><li>Revenue of $187.83M (+5.8% Y/Y) <font color=\"green\">beats by $9.32M</font>.</li><li>Shares <font color=\"green\">+3.24%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17725896-mesa-air-group-reports-fourth-quarter-and-full-year-fiscal-2019-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3525647\" data-linked=\"Mesa Air EPS in-line, beats on revenue\" data-tweet=\"$MESA - Mesa Air EPS in-line, beats on revenue https://seekingalpha.com/news/3525647-mesa-air-eps-in-line-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3525647-mesa-air-eps-in-line-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525637\" data-ts=\"1576096941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525637-vale-upgraded-antofagasta-downgraded-jefferies-in-mining-shuffle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vale upgraded, Antofagasta downgraded at Jefferies in mining shuffle</a></h4><ul><li>Vale (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='green'>+2.2%</font>) is higher after Jefferies <a href=\"https://thefly.com/thestreet/realmoney/index.php/VALE;ANFGY;FCX;FQVLFid3005213/VALE;ANFGY;FCX;FQVLF-Jefferies-ups-Vale-downgrades-Antofagasta-in-metals--mining-rating-shuffle\" target=\"_blank\">upgrades shares to Buy</a> from Hold with a $16 price target, up from $13, as part of a broader sector note on metals and mining.</li><li>Jefferies analyst Christopher Lafemina expects miners as a whole to benefit from ongoing strength in iron ore and the beginning of a cyclical recovery in copper and other industrial commodities in 2020.</li><li>On Vale specifically, Lafemina cites his \"stronger for longer\" iron ore view as well as valuation and what he sees as operational upside.</li><li>In  downgrading Antofagasta (<a href='https://seekingalpha.com/symbol/ANFGF' title='Antofagasta plc'>OTC:ANFGF</a>) to Hold from Buy, the analyst expects the company to benefit from his bullish view on copper prices but he sees capex risk along with geopolitical risk in Chile, leading him to view the shares as fairly valued.</li><li>Vale's average <a href=\"https://seekingalpha.com/symbol/VALE/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Bullish, but both its <a href=\"https://seekingalpha.com/symbol/VALE/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> and <a href=\"https://seekingalpha.com/symbol/VALE/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525637\" data-linked=\"Vale upgraded, Antofagasta downgraded at Jefferies in mining shuffle\" data-tweet=\"$VALE $ANFGF $ANFGY - Vale upgraded, Antofagasta downgraded at Jefferies in mining shuffle https://seekingalpha.com/news/3525637-vale-upgraded-antofagasta-downgraded-jefferies-in-mining-shuffle?source=tweet\" data-url=\"https://seekingalpha.com/news/3525637-vale-upgraded-antofagasta-downgraded-jefferies-in-mining-shuffle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525636\" data-ts=\"1576096909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRE\" target=\"_blank\">APRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525636-aprea-adds-to-aprminus-246-stoked-rally-shares-up-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aprea adds to APR-246-stoked rally, shares up 17%</a></h4><ul><li>Relatively recent IPO Aprea Therapeutics (<a href='https://seekingalpha.com/symbol/APRE' title='Aprea Therapeutics, Inc.'>APRE</a> <font color=\"green\">+17.2%</font>) is up on average volume, a modest 127K shares, adding to its breakout after a <a href=\"https://seekingalpha.com/pr/17722277-aprea-therapeutics-presents-results-from-u-s-phase-ib-ii-clinical-trial-of-aprminus-246-and\" target=\"_blank\">data presentation</a> on lead candidate APR-246 at ASH on Monday.</li><li>Results from a Phase 1b/2 clinical trial in MDS and AML patients showed an overall response rate &#40;ORR&#41; of 88%, including a 61% complete remission rate in MDS participants. Median duration of response was 8.4 months and median duration of complete remission was 7.3 months.</li><li>A pivotal <a href=\"https://clinicaltrials.gov/ct2/show/NCT03745716?lead=aprea+therapeutics&amp;draw=2&amp;rank=2\" target=\"_blank\">Phase 3 study</a> assessing the combination of APR-246 and chemo agent azacitidine (Celgene's Vidaza) for the first-line treatment of TP53 mutation-positive MDS is in process.</li><li>Small molecule APR-246 reactivates a tumor suppressor gene called p53.</li><li>#ASH19</li></ul><div class=\"tiny-share-widget\" data-id=\"3525636\" data-linked=\"Aprea adds to APR-246-stoked rally, shares up 17%\" data-tweet=\"$APRE - Aprea adds to APR-246-stoked rally, shares up 17% https://seekingalpha.com/news/3525636-aprea-adds-to-aprminus-246-stoked-rally-shares-up-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3525636-aprea-adds-to-aprminus-246-stoked-rally-shares-up-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525633\" data-ts=\"1576096020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525633-freeport-mcmoranplus-12-in-week-copper-rallies-to-five-month-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Freeport McMoRan +12% in a week as copper rallies to five-month high</a></h4><ul><li>Freeport McMoRan (<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color=\"green\">+4.2%</font>) is among today's three biggest gainers on the S&amp;P 500 and is now up more than 12% since last Friday, as <a href=\"https://www.reuters.com/article/global-metals/metals-copper-hits-highest-level-since-july-on-hopes-of-u-s-tariffs-delay-idUSL4N28L29L\" target=\"_blank\">copper prices touch their highest since July</a>; Comex copper currently <font color=\"green\">+1.1%</font> to $2.795/lb., up 2.8% so far this week.</li><li>Also on the move: <a href='https://seekingalpha.com/symbol/HBM' title='Hudbay Minerals Inc.'>HBM</a> <font color=\"green\">+6.1%</font>, <a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color=\"green\">+3.1%</font>, <a href='https://seekingalpha.com/symbol/SCCO' title='Southern Copper Corporation'>SCCO</a> <font color=\"green\">+2.1%</font>.</li><li>Copper prices <a href=\"https://www.mining.com/copper-price-rally-builds-on-all-time-high-china-imports/\" target=\"_blank\">gained momentum</a> early this week after trade data showed Chinese imports of refined metal rebounding and concentrate shipments setting a fresh  all-time high.</li><li>Hopes also are high that the U.S. will delay imposing more trade tariffs on goods from China, which would signal a pause in the dispute that has sapped metals demand.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/JJCTF' title='iPath Bloomberg Copper Subindex Total Return ETN'>JJCTF</a>, <a href='https://seekingalpha.com/symbol/COPX' title='Global X Copper Miners ETF'>COPX</a>, <a href='https://seekingalpha.com/symbol/CPER' title='United States Commodity Index Funds Trust - United States Copper Index Fund'>CPER</a>, <a href='https://seekingalpha.com/symbol/JJC' title='iPath Series B Bloomberg Copper Subindex Total Return ETN'>JJC</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3525633\" data-linked=\"Freeport McMoRan +12% in a week as copper rallies to five-month high\" data-tweet=\"$FCX $HBM $TECK - Freeport McMoRan +12% in a week as copper rallies to five-month high https://seekingalpha.com/news/3525633-freeport-mcmoranplus-12-in-week-copper-rallies-to-five-month-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3525633-freeport-mcmoranplus-12-in-week-copper-rallies-to-five-month-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525631\" data-ts=\"1576095327\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAXR\" target=\"_blank\">MAXR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525631-maxar-debt-sale-funds-released-from-escrow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maxar debt-sale funds released from escrow</a></h4><ul>   <li>Maxar Technologies (<a href=\"http://seekingalpha.com/symbol/MAXR\" target=\"_blank\">MAXR</a> <font color=\"red\">-4.6%</font>) says proceeds from the sale of 9.75% senior debt by its SSL Robotics arm have been <a href=\"https://seekingalpha.com/pr/17725812-maxar-technologies-announces-release-of-proceeds-of-notes-offering-from-escrow-and\" target=\"_blank\">released from escrow</a>.</li>    <li>The company assumed SSL Robotics' obligations as issuer, and the notes (due 2023) became senior, first-priority secured obligations.</li>    <li>Maxar used the released proceeds along with proceeds from its Palo Alto sale-leaseback to repay all borrowings under its revolving credit facility, and term loans A-1 and A-2 under its syndicated credit facility.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525631\" data-linked=\"Maxar debt-sale funds released from escrow\" data-tweet=\"$MAXR - Maxar debt-sale funds released from escrow https://seekingalpha.com/news/3525631-maxar-debt-sale-funds-released-from-escrow?source=tweet\" data-url=\"https://seekingalpha.com/news/3525631-maxar-debt-sale-funds-released-from-escrow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525629\" data-ts=\"1576094029\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEL\" target=\"_blank\">GEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525629-genesis-energy-murphy-oil-ink-gulf-of-mexico-transportation-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genesis Energy, Murphy Oil ink Gulf of Mexico transportation deal</a></h4><ul><li>Genesis Energy (<a href='https://seekingalpha.com/symbol/GEL' title='Genesis Energy, L.P.'>GEL</a> <font color='green'>+2.6%</font>) enjoys strong gains after entering an agreement with Murphy Oil (<a href='https://seekingalpha.com/symbol/MUR' title='Murphy Oil Corporation'>MUR</a> <font color='green'>+0.6%</font>) to <a href=\"https://seekingalpha.com/pr/17724740-genesis-energy-l-p-signs-new-deepwater-gulf-of-mexico-transportation-agreements\" target=\"_blank\">provide downstream transportation services</a> for all oil and gas production associated with the deepwater Gulf of Mexico Khaleesi/Mormont and Samurai field developments through MUR's King's Quay floating production system.</li><li>The King\u2019s Quay FPS will process as much as 80K bbl/day of oil and as much as 100M cf/day of gas from the two developments.</li><li>No capital will be required from GEL to connect King's Quay FPS to  its assets; first deliveries of oil and gas are anticipated in  mid-2022.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525629\" data-linked=\"Genesis Energy, Murphy Oil ink Gulf of Mexico transportation deal\" data-tweet=\"$GEL $MUR - Genesis Energy, Murphy Oil ink Gulf of Mexico transportation deal https://seekingalpha.com/news/3525629-genesis-energy-murphy-oil-ink-gulf-of-mexico-transportation-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3525629-genesis-energy-murphy-oil-ink-gulf-of-mexico-transportation-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525623\" data-ts=\"1576092141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVX\" target=\"_blank\">CVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525623-many-energy-writeoffs-likely-following-chevron-10b-plus-charge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Many more energy writeoffs likely following Chevron $10B-plus charge</a></h4><ul><li>Shares of big gas producers are mostly lower after Chevron (<a href='https://seekingalpha.com/symbol/CVX' title='Chevron Corporation'>CVX</a> <font color='red'>-1.3%</font>) announced a <a href=\"https://seekingalpha.com/news/3525360-chevron-to-take-10b-plus-asset-writedown\" target=\"_blank\">$10B-$11B charge</a> against the value of its assets and  a reduced forecast for commodity prices: <a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color=\"red\">-3.3%</font>, <a href='https://seekingalpha.com/symbol/EQT' title='EQT Corporation'>EQT</a> <font color=\"red\">-3.1%</font>, <a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Company'>SWN</a> <font color=\"red\">-1.4%</font>, <a href='https://seekingalpha.com/symbol/GPOR' title='Gulfport Energy Corporation'>GPOR</a> <font color=\"red\">-1.4%</font>, <a href='https://seekingalpha.com/symbol/COG' title='Cabot Oil & Gas Corporation'>COG</a> <font color=\"red\">-0.3%</font>, <a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a> <font color=\"green\">+0.2%</font>, <a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a> <font color=\"green\">+1.6%</font>.</li><li>The price of natural gas has been nearly cut in half over the past year, and CVX's move marked a concession that some of its holdings  would <a href=\"https://www.morningstar.com/news/dow-jones/201912116999/shares-of-oil-giants-fall-after-chevrons-10-billion-charge\" target=\"_blank\">not be profitable anytime soon</a>, as it slashed the value of properties such as its U.S. shale holdings in Appalachia.</li><li><a href=\"https://www.reuters.com/article/us-chevron-outlook-natgas/chevron-charge-points-to-billions-more-in-gas-writedowns-analysts-idUSKBN1YF1WW\" target=\"_blank\">Many more writeoffs likely are in store</a>, Berenberg analysts say, as CVX's move \"highlights that many companies are still carrying assets on their balance sheet that were acquired or developed with cost structures that are materially higher than today\u2019s levels.\"</li><li>The move also <a href=\"https://finance.yahoo.com/news/chevron-ushers-oil-era-sober-165105263.html\" target=\"_blank\">shines a spotlight</a> on rival Exxon Mobil (<a href='https://seekingalpha.com/symbol/XOM' title='Exxon Mobil Corporation'>XOM</a>), which has <a href=\"https://twitter.com/JavierBlas/status/1204771033032601601\" target=\"_blank\">written down just $2.5B</a> of its disastrous $42B (including debt) 2010 deal for gas producer XTO.</li><li>XOM also sticks out for its giant capex budget - bigger than CVX's by more than half - leaving no room for buybacks or even to fully cover its dividend, says Bloomberg's Liam Denning.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Trust II - ProShares Ultra Bloomberg Natural Gas'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GASL' title='Direxion Daily Natural Gas Related Bull 3x Shares ETF'>GASL</a>, <a href='https://seekingalpha.com/symbol/FCG' title='First Trust Natural Gas ETF'>FCG</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas'>KOLD</a>, <a href='https://seekingalpha.com/symbol/GASX' title='Direxion Daily Natural Gas Related Bear 3X Shares ETF'>GASX</a>, <a href='https://seekingalpha.com/symbol/UNL' title='United States 12 Month Natural Gas Fund, LP'>UNL</a>, <a href='https://seekingalpha.com/symbol/GAZB' title='iPath Series B Bloomberg Natural Gas Subindex Total Return ETN'>GAZB</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath Series B Bloomberg Natural Gas Subindex Total Return ETN'>GAZ</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3525623\" data-linked=\"Many more energy writeoffs likely following Chevron $10B-plus charge\" data-tweet=\"$CVX $CHK $EQT - Many more energy writeoffs likely following Chevron $10B-plus charge https://seekingalpha.com/news/3525623-many-energy-writeoffs-likely-following-chevron-10b-plus-charge?source=tweet\" data-url=\"https://seekingalpha.com/news/3525623-many-energy-writeoffs-likely-following-chevron-10b-plus-charge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525621\" data-ts=\"1576091684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAKE\" target=\"_blank\">CAKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525621-cheesecake-factory-dragged-mall-malaise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheesecake Factory dragged into mall malaise</a></h4><ul> <li>Cheesecake Factory (NASDAQ:<a href='https://seekingalpha.com/symbol/CAKE' title='The Cheesecake Factory Incorporated'>CAKE</a>) is <font color=\"red\">1.90% lower</font> on a downward swing that seems to be related to warnings pouring out of the mall sector.</li> <li>Shares of CAKE are down more than 5% since the restaurant operator reported Q3 earnings.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525613-no-holiday-cheer-in-mall-sector\" target=\"_blank\">No holiday cheer in the mall sector</a> (Dec. 11)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3525621\" data-linked=\"Cheesecake Factory dragged into mall malaise\" data-tweet=\"$CAKE - Cheesecake Factory dragged into mall malaise https://seekingalpha.com/news/3525621-cheesecake-factory-dragged-mall-malaise?source=tweet\" data-url=\"https://seekingalpha.com/news/3525621-cheesecake-factory-dragged-mall-malaise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525619\" data-ts=\"1576090897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525619-energy-materials-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials  - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"green\">+117%</font>. Sibanye Gold (NYSE:<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye Gold Limited'>SBGL</a>) <font color=\"green\">+8%</font>. Hudbay Minerals (NYSE:<a href='https://seekingalpha.com/symbol/HBM' title='Hudbay Minerals Inc.'>HBM</a>) <font color=\"green\">+8%</font>. Exterran (NYSE:<a href='https://seekingalpha.com/symbol/EXTN' title='Exterran Corporation'>EXTN</a>) <font color=\"green\">+7%</font>. Rosehill Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/ROSE' title='Rosehill Resources Inc.'>ROSE</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>FTS International (NYSE:<a href='https://seekingalpha.com/symbol/FTSI' title='FTS International, Inc.'>FTSI</a>) <font color=\"red\">-11%</font>. TuanChe (NASDAQ:<a href='https://seekingalpha.com/symbol/TC' title='TuanChe Limited'>TC</a>) <font color=\"red\">-10%</font>. Lightbridge (NASDAQ:<a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corporation'>LTBR</a>) <font color=\"red\">-9%</font>. KLX Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/KLXE' title='KLX Energy Services Holdings, Inc.'>KLXE</a>) <font color=\"red\">-7%</font>. Core Molding Technologies (NYSEMKT:<a href='https://seekingalpha.com/symbol/CMT' title='Core Molding Technologies, Inc.'>CMT</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525619\" data-linked=\"Energy/Materials  - Top 5 Gainers / Losers\" data-tweet=\"$CEI $SBGL $HBM - Energy/Materials - Top 5 Gainers / Losers https://seekingalpha.com/news/3525619-energy-materials-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525619-energy-materials-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525614\" data-ts=\"1576089977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRXC\" target=\"_blank\">TRXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525614-transenterix-to-reverse-split-shares-1-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransEnterix to reverse split shares 1:13</a></h4><ul><li>TransEnterix (<a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color=\"red\">-7.7%</font>) will execute a <a href=\"https://seekingalpha.com/pr/17725613-transenterix-announces-one-for-thirteen-reverse-stock-split-of-common-stock\" target=\"_blank\">1:13 reverse split</a> of its common stock today at 5:00 pm ET. Post-split trading will commence tomorrow, December 12, at the open.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525614\" data-linked=\"TransEnterix to reverse split shares 1:13\" data-tweet=\"$TRXC - TransEnterix to reverse split shares 1:13 https://seekingalpha.com/news/3525614-transenterix-to-reverse-split-shares-1-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3525614-transenterix-to-reverse-split-shares-1-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525613\" data-ts=\"1576089915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525613-no-holiday-cheer-in-mall-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No holiday cheer in the mall sector</a></h4><ul> <li>The mall sector is having a rough day amid warnings on higher markdown activity from American Eagle Outfitters (<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a> <font color=\"red\">-6.2%</font>), as well as warnings on traffic from both Children's Place (<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place, Inc.'>PLCE</a> <font color=\"red\">-23.3%</font>) and Dave &amp; Buster's Entertainment (<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color=\"red\">-6.4%</font>).</li><li>Companies with a higher mix of store sales to online sales seem to be hurting the most.</li> <li>Notable decliners include Stage Stores (<a href='https://seekingalpha.com/symbol/SSI' title='Stage Stores, Inc.'>SSI</a> <font color=\"red\">-8.5%</font>), Tailored Brands (<a href='https://seekingalpha.com/symbol/TLRD' title='Tailored Brands, Inc.'>TLRD</a> <font color=\"red\">-6.8%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color=\"red\">-8.7%</font>), Chico's FAS (<a href='https://seekingalpha.com/symbol/CHS' title='Chico&#39;s FAS, Inc.'>CHS</a> <font color=\"red\">-6%</font>), Abercrombie &amp; Fitch (<a href='https://seekingalpha.com/symbol/ANF' title='Abercrombie & Fitch Co.'>ANF</a> <font color=\"red\">-6.2%</font>), Genesco (<a href='https://seekingalpha.com/symbol/GCO' title='Genesco Inc.'>GCO</a> <font color=\"red\">-6.1%</font>), Ascena Retail Group (<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group, Inc.'>ASNA</a> <font color=\"red\">-2.2%</font>), J.C. Penney (<a href='https://seekingalpha.com/symbol/JCP' title='J. C. Penney Company, Inc.'>JCP</a> <font color=\"red\">-3.4%</font>), Tilly's (<a href='https://seekingalpha.com/symbol/TLYS' title='Tilly&#39;s, Inc.'>TLYS</a> <font color=\"red\">-4%</font>), Buckle (<a href='https://seekingalpha.com/symbol/BKE' title='The Buckle, Inc.'>BKE</a> <font color=\"red\">-2.8%</font>), L Brands (<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color=\"red\">-2.6%</font>), Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color=\"red\">-3.1%</font>), Cato (<a href='https://seekingalpha.com/symbol/CATO' title='The Cato Corporation'>CATO</a> <font color=\"red\">-2.2%</font>), Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color=\"red\">-2.6%</font>), Michaels (<a href='https://seekingalpha.com/symbol/MIK' title='The Michaels Companies, Inc.'>MIK</a> <font color=\"red\">-3%</font>), RTW Retailwinds (<a href='https://seekingalpha.com/symbol/RTW' title='RTW Retailwinds, Inc.'>RTW</a> <font color=\"red\">-2.3%</font>), Pier 1 Imports (<a href='https://seekingalpha.com/symbol/PIR' title='Pier 1 Imports, Inc.'>PIR</a> <font color=\"red\">-3.2%</font>), Dillard's (<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s, Inc.'>DDS</a> <font color=\"red\">-3%</font>), Express (<a href='https://seekingalpha.com/symbol/EXPR' title='Express, Inc.'>EXPR</a> <font color=\"red\">-8.7%</font>) and Shoe Carnival (<a href='https://seekingalpha.com/symbol/SCVL' title='Shoe Carnival, Inc.'>SCVL</a> <font color=\"red\">-1.6%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3525613\" data-linked=\"No holiday cheer in the mall sector\" data-tweet=\"$AEO $PLCE $PLAY - No holiday cheer in the mall sector https://seekingalpha.com/news/3525613-no-holiday-cheer-in-mall-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3525613-no-holiday-cheer-in-mall-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525610\" data-ts=\"1576088915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPS\" target=\"_blank\">UPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525610-ups-falls-after-bmo-capital-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UPS falls after BMO Capital warning</a></h4><ul> <li>Shares of UPS (<a href='https://seekingalpha.com/symbol/UPS' title='United Parcel Service, Inc.'>UPS</a> <font color='red'>-1.2%</font>) fall after BMO Capital Markets lowers the shipper to a Market Perform rating after having it slotted at Outperform.</li> <li>The firm expects UPS to struggle improving its profitability and free cash flow moving forward.</li> <li>\"While we believe that UPS may be able to deliver positive operating leverage (excluding the impact of pension) in the near-term as a result of strong volumes and efficiency gains from past/ongoing productivity investments, we\u2019re not convinced a positive trend in operating margins in U.S. domestic operations can be sustained over the medium-term given a significant projected rise in B2C volumes. Other key elements to the valuation are capital intensity and FCF where we see limited opportunity for improvement,\" notes the BMO analyst team.</li> <li>The average sell-side rating on UPS is still Bullish, but the Quant Rating is at <a href=\"https://seekingalpha.com/symbol/UPS/ratings/quant-ratings\" target=\"_blank\">Neutral</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525610\" data-linked=\"UPS falls after BMO Capital warning\" data-tweet=\"$UPS - UPS falls after BMO Capital warning https://seekingalpha.com/news/3525610-ups-falls-after-bmo-capital-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3525610-ups-falls-after-bmo-capital-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525609\" data-ts=\"1576088342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AYX\" target=\"_blank\">AYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525609-alteryx-down-11-investor-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alteryx down 11% before investor presentation</a></h4><ul><li>Data analytics outfit Alteryx (<a href='https://seekingalpha.com/symbol/AYX' title='Alteryx, Inc.'>AYX</a> <font color=\"red\">-10.8%</font>) slumps on double normal volume on no particular news. CFO Kevin Rubin delivered a corporate overview today at a Raymond James conference in New York that apparently did not contain anything unexpected.</li><li>Shares are down <font color=\"red\">15%</font> since touching $112.82 on Friday, December 6.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525609\" data-linked=\"Alteryx down 11% before investor presentation\" data-tweet=\"$AYX - Alteryx down 11% before investor presentation https://seekingalpha.com/news/3525609-alteryx-down-11-investor-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3525609-alteryx-down-11-investor-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525606\" data-ts=\"1576087816\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOGM\" target=\"_blank\">LOGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525606-logmein-gains-on-4b-deal-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LogMeIn gains on $4B deal talks</a></h4><ul><li>PE firm Francisco Partners Management is partnering with Elliott Management in a bid to take LogMeIn (NASDAQ:<a href='https://seekingalpha.com/symbol/LOGM' title='LogMeIn, Inc.'>LOGM</a>) private, according to <a href=\"https://www.bloomberg.com/news/articles/2019-12-11/francisco-partners-elliott-said-to-be-in-talks-to-buy-logmein\" target=\"_blank\">Bloomberg sources</a>.</li><li>The firms are in advanced talks for the more than $4B deal, which could be announced in the coming weeks.</li><li>No final decision has been made, and the details could still change.</li><li>LogMeIn shares raised more than <font color=\"green\">10%</font> after the story. LOGM is currently<font color=\"green\"> up 7.3%</font> to $79.43.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525606\" data-linked=\"LogMeIn gains on $4B deal talks\" data-tweet=\"$LOGM - LogMeIn gains on $4B deal talks https://seekingalpha.com/news/3525606-logmein-gains-on-4b-deal-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3525606-logmein-gains-on-4b-deal-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525604\" data-ts=\"1576087636\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525604-fpay-and-glg-among-financial-gainers-curo-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FPAY and GLG among financial gainers; CURO leads losers</a></h4><ul><li><b>Gainers:</b> 360 Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/QFIN' title='360 Finance, Inc.'>QFIN</a>) <font color=\"green\">+10%</font>. FlexShopper (NASDAQ:<a href='https://seekingalpha.com/symbol/FPAY' title='FlexShopper, Inc.'>FPAY</a>) <font color=\"green\">+6%</font>. Bat Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GLG' title='Bat Group, Inc.'>GLG</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> CURO Group Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CURO' title='CURO Group Holdings Corp.'>CURO</a>) <font color=\"red\">-9%</font>. EverQuote (NASDAQ:<a href='https://seekingalpha.com/symbol/EVER' title='EverQuote, Inc.'>EVER</a>) <font color=\"red\">-8%</font>. Weidai (NYSE:<a href='https://seekingalpha.com/symbol/WEI' title='Weidai Ltd.'>WEI</a>) <font color=\"red\">-6%</font>. LendingTree (NASDAQ:<a href='https://seekingalpha.com/symbol/TREE' title='LendingTree, Inc.'>TREE</a>) <font color=\"red\">-6%</font>. Wheeler Real Estate Investment Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/WHLR' title='Wheeler Real Estate Investment Trust, Inc.'>WHLR</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525604\" data-linked=\"FPAY and GLG among financial gainers; CURO leads losers\" data-tweet=\"$QFIN $FPAY $GLG - FPAY and GLG among financial gainers; CURO leads losers https://seekingalpha.com/news/3525604-fpay-and-glg-among-financial-gainers-curo-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525604-fpay-and-glg-among-financial-gainers-curo-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525602\" data-ts=\"1576087251\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525602-research-frontiers-and-nn-in-industrial-gainers-columbus-mckinnon-in-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Research Frontiers and NN in industrial gainers; Columbus McKinnon in losers</a></h4><ul><li><b>Gainers: </b>Hebron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a>) <font color=\"green\">+12%</font>. Air Industries (NYSEMKT:<a href='https://seekingalpha.com/symbol/AIRI' title='Air Industries Group'>AIRI</a>) <font color=\"green\">+10%</font>. NN (NASDAQ:<a href='https://seekingalpha.com/symbol/NNBR' title='NN, Inc.'>NNBR</a>) <font color=\"green\">+7%</font>. Limbach Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LMB' title='Limbach Holdings, Inc.'>LMB</a>) <font color=\"green\">+7%</font>. Research Frontiers (NASDAQ:<a href='https://seekingalpha.com/symbol/REFR' title='Research Frontiers Incorporated'>REFR</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Columbus McKinnon (NASDAQ:<a href='https://seekingalpha.com/symbol/CMCO' title='Columbus McKinnon Corporation'>CMCO</a>) <font color=\"red\">-9%</font>. NF Energy Saving (NASDAQ:<a href='https://seekingalpha.com/symbol/BIMI' title='NF Energy Saving Corporation'>BIMI</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525602\" data-linked=\"Research Frontiers and NN in industrial gainers; Columbus McKinnon in losers\" data-tweet=\"$HEBT $AIRI $NNBR - Research Frontiers and NN in industrial gainers; Columbus McKinnon in losers https://seekingalpha.com/news/3525602-research-frontiers-and-nn-in-industrial-gainers-columbus-mckinnon-in-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525602-research-frontiers-and-nn-in-industrial-gainers-columbus-mckinnon-in-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525598\" data-ts=\"1576086198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLCM\" target=\"_blank\">BLCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525598-bellicum-out-licenses-safety-switch-technology-to-md-anderson-shares-up-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bellicum out-licenses safety switch technology to MD Anderson; shares up 15%</a></h4><ul><li>Nano cap Bellicum Pharmaceuticals (<a href='https://seekingalpha.com/symbol/BLCM' title='Bellicum Pharmaceuticals, Inc.'>BLCM</a> <font color=\"green\">+14.6%</font>) is up on 60% higher volume on the heels of its <a href=\"https://seekingalpha.com/pr/17724878-bellicum-pharmaceuticals-licenses-caspacide-safety-switch-to-md-anderson\" target=\"_blank\">out-licensing deal</a> with MD Anderson Cancer Center for its <a href=\"https://www.bellicum.com/technology/caspacide/\" target=\"_blank\">CaspaCIDe</a> safety switch technology.</li><li>Under the terms of the agreement, Bellicum will receive $5M upfront, undisclosed milestones and royalties on net sales.</li><li>CaspaCIDe is designed to protect patients receiving cell-based therapies from cytokine release syndrome or neurotoxicity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525598\" data-linked=\"Bellicum out-licenses safety switch technology to MD Anderson; shares up 15%\" data-tweet=\"$BLCM - Bellicum out-licenses safety switch technology to MD Anderson; shares up 15% https://seekingalpha.com/news/3525598-bellicum-out-licenses-safety-switch-technology-to-md-anderson-shares-up-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3525598-bellicum-out-licenses-safety-switch-technology-to-md-anderson-shares-up-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525597\" data-ts=\"1576085991\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525597-gme-mdgl-mbot-and-olli-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GME, MDGL, MBOT and OLLI among midday movers</a></h4><ul><li><strong>Gainers:</strong> Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"green\">+130%</font>.</li><li>Marinus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals, Inc.'>MRNS</a>) <font color=\"green\">+30%</font>.</li><li>Centogene (NASDAQ:<a href='https://seekingalpha.com/symbol/CNTG' title='Centogene N.V.'>CNTG</a>) <font color=\"green\">+22%</font>.</li><li>Photronics (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAB' title='Photronics, Inc.'>PLAB</a>) <font color=\"green\">+20%</font>.</li><li>Abeona Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>) <font color=\"green\">+18%</font>.</li><li>Genetic Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/GENE' title='Genetic Technologies Limited'>GENE</a>) <font color=\"green\">+18%</font>.</li><li>Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc.'>MBOT</a>) <font color=\"green\">+18%</font>.</li><li>Steel Connect (NASDAQ:<a href='https://seekingalpha.com/symbol/STCN' title='Steel Connect, Inc.'>STCN</a>) <font color=\"green\">+16%</font>.</li><li>Trans World Entertainment  (NASDAQ:<a href='https://seekingalpha.com/symbol/TWMC' title='Trans World Entertainment Corporation'>TWMC</a>) <font color=\"green\">+15%</font>.</li><li>Ollie's Bargain Outlet (NASDAQ:<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings, Inc.'>OLLI</a>) <font color=\"green\">+15%</font>.</li><li><strong>Losers: </strong>Correvio Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CORV' title='Correvio Pharma Corp.'>CORV</a>) <font color=\"red\">-66%</font>.</li><li>Iterum Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ITRM' title='Iterum Therapeutics plc'>ITRM</a>) <font color=\"red\">-36%</font>.</li><li>United Natural Foods (NYSE:<a href='https://seekingalpha.com/symbol/UNFI' title='United Natural Foods, Inc.'>UNFI</a>) <font color=\"red\">-25%</font>.</li><li>The Children's Place (NASDAQ:<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place, Inc.'>PLCE</a>) <font color=\"red\">-23%</font>.</li><li>Technical Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"red\">-17%</font>.</li><li>GameStop (NYSE:<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a>) <font color=\"red\">-17%</font>.</li><li>Taronis Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/TRNX' title='Taronis Technologies, Inc.'>TRNX</a>) <font color=\"red\">-16%</font>.</li><li>Aethlon Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a>) <font color=\"red\">-15%</font>.</li><li>IMAC Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/IMAC' title='IMAC Holdings, Inc.'>IMAC</a>) <font color=\"red\">-15%</font>.</li><li>Madrigal Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a>) <font color=\"red\">-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525597\" data-linked=\"GME, MDGL, MBOT and OLLI among midday movers\" data-tweet=\"$CEI $MRNS $CNTG - GME, MDGL, MBOT and OLLI among midday movers https://seekingalpha.com/news/3525597-gme-mdgl-mbot-and-olli-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525597-gme-mdgl-mbot-and-olli-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525596\" data-ts=\"1576085702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLNG\" target=\"_blank\">GLNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525596-golar-lng-started-sell-rating-goldman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Golar LNG started with Sell rating at Goldman</a></h4><ul><li>Golar LNG (<a href='https://seekingalpha.com/symbol/GLNG' title='Golar LNG Limited'>GLNG</a> <font color='red'>-2.4%</font>) sinks after Goldman Sachs initiated coverage with a  <a href=\"https://thefly.com/thestreet/realmoney/index.php/GLNGid3004995/GLNG-Golar-LNG-initiated-with-a-Sell-at-Goldman-Sachs\" target=\"_blank\">Sell rating</a> and $12 price target.</li><li>Goldman analyst Sahar Islam notes LNG supply  additions peaked in 2018-19 and will be slower from 2020-24, adding that while shipping rates have increased in the short term thanks  to the new LNG supply entering the market, this incremental positive  will slow starting next year.</li><li>GLNG's average <a href=\"https://seekingalpha.com/symbol/GLNG/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> and <a href=\"https://seekingalpha.com/symbol/GLNG/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> are Bullish, while its <a href=\"https://seekingalpha.com/symbol/GLNG/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525596\" data-linked=\"Golar LNG started with Sell rating at Goldman\" data-tweet=\"$GLNG - Golar LNG started with Sell rating at Goldman https://seekingalpha.com/news/3525596-golar-lng-started-sell-rating-goldman?source=tweet\" data-url=\"https://seekingalpha.com/news/3525596-golar-lng-started-sell-rating-goldman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525594\" data-ts=\"1576085266\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALKS\" target=\"_blank\">ALKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525594-fda-warns-alkermes-over-vivitrol-misbranding\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA warns Alkermes over Vivitrol misbranding</a></h4><ul><li>Alkermes plc (<a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a> <font color=\"red\">-2.9%</font>) has received a <a href=\"https://www.fda.gov/news-events/press-announcements/fda-issues-warning-letter-not-including-most-serious-risks-advertisement-medication-assisted\" target=\"_blank\">Warning Letter</a> from the FDA regarding misbranding of alcohol and opioid abuse prevention med <a href=\"https://www.vivitrol.com/\" target=\"_blank\">Vivitrol</a> (naltrexone extended-release injectable suspension).</li><li>Specifically, the agency cited a print ad that failed to adequately communicate the most serious risks, including vulnerability to opioid overdose.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525594\" data-linked=\"FDA warns Alkermes over Vivitrol misbranding\" data-tweet=\"$ALKS - FDA warns Alkermes over Vivitrol misbranding https://seekingalpha.com/news/3525594-fda-warns-alkermes-over-vivitrol-misbranding?source=tweet\" data-url=\"https://seekingalpha.com/news/3525594-fda-warns-alkermes-over-vivitrol-misbranding\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525593\" data-ts=\"1576085186\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525593-dish-media-freewheel-team-up-on-targeted-ads\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dish Media, FreeWheel team up on targeted ads</a></h4><ul>   <li>Dish Media (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color=\"green\">+1%</font>) is <a href=\"https://www.lightreading.com/video/dish-media-teams-with-comcasts-freewheel-unit-on-targeted-tv-ads-/d/d-id/756219?_mc=RSS_LR_EDT&amp;utm_source=dlvr.it&amp;utm_medium=twitter\" target=\"_blank\">partnering with Comcast's FreeWheel</a> (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color=\"red\">-1.7%</font>) on targeted advertising.</li>    <li>The team-up will enable linear inventory allocation and a view of performance across traditional, demographic-based purchases and household-level addressable campaigns, they say.</li>    <li>Addressing those two inventories with different platforms introduces supply and pricing conflicts along with clearance issues and inconsistent delivery on addressable campaigns, while FreeWheel says its unified approach lets customers consider the full pool of demand.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525593\" data-linked=\"Dish Media, FreeWheel team up on targeted ads\" data-tweet=\"$DISH $CMCSA - Dish Media, FreeWheel team up on targeted ads https://seekingalpha.com/news/3525593-dish-media-freewheel-team-up-on-targeted-ads?source=tweet\" data-url=\"https://seekingalpha.com/news/3525593-dish-media-freewheel-team-up-on-targeted-ads\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525586\" data-ts=\"1576083549\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525586-eastman-kodak-leads-consumer-gainers-peloton-interactive-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eastman Kodak leads consumer gainers; Peloton Interactive among losers</a></h4><ul><li><b>Gainers: </b>Eastman Kodak (NYSE:<a href='https://seekingalpha.com/symbol/KODK' title='Eastman Kodak Company'>KODK</a>) <font color=\"green\">+12%</font>. Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp.'>SOLO</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Vera Bradley (NASDAQ:<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley, Inc.'>VRA</a>) <font color=\"red\">-9%</font>. BRP (NASDAQ:<a href='https://seekingalpha.com/symbol/DOOO' title='BRP Inc.'>DOOO</a>) <font color=\"red\">-6%</font>. Peloton Interactive (NASDAQ:<a href='https://seekingalpha.com/symbol/PTON' title='Peloton Interactive, Inc.'>PTON</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525586\" data-linked=\"Eastman Kodak leads consumer gainers; Peloton Interactive among losers\" data-tweet=\"$KODK $SOLO $VRA - Eastman Kodak leads consumer gainers; Peloton Interactive among losers https://seekingalpha.com/news/3525586-eastman-kodak-leads-consumer-gainers-peloton-interactive-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525586-eastman-kodak-leads-consumer-gainers-peloton-interactive-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525585\" data-ts=\"1576083515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGNX\" target=\"_blank\">MGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525585-macrogenics-down-3-on-uncertainty-of-margetuximab-survival-benefit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MacroGenics down 3% on uncertainty of margetuximab survival benefit</a></h4><ul><li>MacroGenics (<a href='https://seekingalpha.com/symbol/MGNX' title='MacroGenics, Inc.'>MGNX</a> <font color=\"red\">-2.9%</font>) is down on double normal volume in response to <a href=\"https://seekingalpha.com/pr/17725469-macrogenics-presents-results-from-sophia-study-of-margetuximab-in-patients-her2-positive\" target=\"_blank\">results </a>from a second interim survival analysis of Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02492711?term=NCT02492711&amp;draw=2&amp;rank=1\" target=\"_blank\">SOPHIA</a>, comparing lead drug margetuximab + chemo to Roche's Herceptin (trastuzumab) + chemo in patients with HER2-positive metastatic breast cancer who have previously received anti-HER2-targeted therapies. The data were presented at the San Antonio Breast Cancer Symposium.</li><li>Overall survival &#40;OS&#41; favored margetuximab, but the separation was not statistically significant. Specifically, median OS was 21.6 months versus 19.8 months for trastuzumab (p=0.326) (first <a href=\"https://seekingalpha.com/news/3508347-macrogenics-down-14-premarket-on-doubts-margetuximab-data\" target=\"_blank\">reported</a> in October). The final OS analysis will be based on 385 events, expected to occur in H2 2020.</li><li>The company says that margetuximab showed a statistically valid <a href=\"https://seekingalpha.com/news/3430058-macrogenics-up-156-premarket-on-positive-margetuximab-data\" target=\"_blank\">improvement </a>in progression-free survival, although the median value (5.8 months) was only a few weeks better than trastuzumab (4.9 months) (p=0.033).</li></ul><div class=\"tiny-share-widget\" data-id=\"3525585\" data-linked=\"MacroGenics down 3% on uncertainty of margetuximab survival benefit\" data-tweet=\"$MGNX - MacroGenics down 3% on uncertainty of margetuximab survival benefit https://seekingalpha.com/news/3525585-macrogenics-down-3-on-uncertainty-of-margetuximab-survival-benefit?source=tweet\" data-url=\"https://seekingalpha.com/news/3525585-macrogenics-down-3-on-uncertainty-of-margetuximab-survival-benefit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525580\" data-ts=\"1576082765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLG\" target=\"_blank\">SLG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525580-sl-green-gains-bull-after-investor-day-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SL Green gains a bull after investor day event</a></h4><ul><li>Bank of America analyst James Feldman upgrades SL Green Realty (<a href='https://seekingalpha.com/symbol/SLG' title='SL Green Realty Corp.'>SLG</a> <font color='green'>+1.1%</font>) to buy from neutral after the REIT's investor day event left the analyst with \"an optimistic view of NYC for 2020 with good demand for new an renovated spaces.\"</li><li>Boosts price target to $103 from $88.</li><li>\"We have been waiting for more clarity on earnings growth, net effective rents, and the 2020 NYC leasing pipeline,\" Feldman wrote in a note.</li><li>Feldman's buy rating contrasts with <a href=\"https://seekingalpha.com/symbol/SLG/ratings/quant-ratings\" target=\"_blank\">Quant rating </a>of Neutral; before this action, <a href=\"https://seekingalpha.com/symbol/SLG/ratings/sell-side-ratings\" target=\"_blank\">Sell-Side average rating</a> was Neutral (5 Very Bullish, 4 Bullish, 10 Neutral, 1 Bearish, 1 Very Bearish).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525268-sl-green-rises-3_5-in-two-day-advance\" target=\"_blank\">SL Green rises 3.5% in two-day advance</a> (Dec. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3525580\" data-linked=\"SL Green gains a bull after investor day event\" data-tweet=\"$SLG - SL Green gains a bull after investor day event https://seekingalpha.com/news/3525580-sl-green-gains-bull-after-investor-day-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3525580-sl-green-gains-bull-after-investor-day-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525578\" data-ts=\"1576082388\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHWY\" target=\"_blank\">CHWY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525578-chewy-sails-past-ipo-lockup-fears\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chewy sails past IPO lockup fears</a></h4><ul> <li>Shares of Chewy (NYSE:<a href='https://seekingalpha.com/symbol/CHWY' title='Chewy, Inc.'>CHWY</a>) are <font color=\"green\">up 5.22%</font> on the day and are now 17.21% higher over the last five sessions.</li> <li>On the positive side of the ledger, William Blair was out with positive comments today and <i>The Wall Street Journal's</i> Heard On The Street column <a href=\"https://www.wsj.com/articles/chewy-finally-looks-appetizing-11575996241\" target=\"_blank\">maintains</a> that the 1.7 forward sales multiple on Chewy is not unreasonable for a rapidly growing company.</li> <li>Perhaps most importantly, the expiration of the Chewy IPO lockup period hasn't created a wave of selling today.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525578\" data-linked=\"Chewy sails past IPO lockup fears\" data-tweet=\"$CHWY - Chewy sails past IPO lockup fears https://seekingalpha.com/news/3525578-chewy-sails-past-ipo-lockup-fears?source=tweet\" data-url=\"https://seekingalpha.com/news/3525578-chewy-sails-past-ipo-lockup-fears\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525576\" data-ts=\"1576082046\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GENE\" target=\"_blank\">GENE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525576-genetic-tech-up-22-on-pending-launch-of-breast-cancer-test\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Genetic Tech up 22% on pending launch of breast cancer test</a></h4><ul><li>Thinly traded nano cap Genetic Technologies Limited (<a href='https://seekingalpha.com/symbol/GENE' title='Genetic Technologies Limited'>GENE</a> <font color=\"green\">+21.6%</font>) is up on almost a 5x surge in volume, albeit on turnover of only 149K shares, in response to its <a href=\"https://seekingalpha.com/pr/17723101-genetype-for-breast-cancer-commissioned-sales-to-commence-first-quarter-2020\" target=\"_blank\">announcement</a> that sales of its third-generation breast cancer test should commence next quarter.</li><li>The company aims to set up 12 clinical sites to demonstrate utility, user experience, reimbursement and distribution.</li><li>The test, called Genetype for Breast Cancer, predicts the risk of disease by combining DNA and mammography data.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525576\" data-linked=\"Genetic Tech up 22% on pending launch of breast cancer test\" data-tweet=\"$GENE - Genetic Tech up 22% on pending launch of breast cancer test https://seekingalpha.com/news/3525576-genetic-tech-up-22-on-pending-launch-of-breast-cancer-test?source=tweet\" data-url=\"https://seekingalpha.com/news/3525576-genetic-tech-up-22-on-pending-launch-of-breast-cancer-test\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525569\" data-ts=\"1576081057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALGT\" target=\"_blank\">ALGT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525569-allegiant-reports-november-traffic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allegiant reports November traffic</a></h4><ul> <li>Allegiant Travel (<a href='https://seekingalpha.com/symbol/ALGT' title='Allegiant Travel Company'>ALGT</a> <font color='green'>+0.1%</font>) <a href=\"https://seekingalpha.com/pr/17725557-allegiant-reports-november-2019-traffic\" sasource=\"qp_sum_news_4\" target=\"_blank\">reports</a> scheduled service revenue passenger miles rose 1.6% to 962.61M in November.</li><li>Scheduled service load factor fell 210 bps to 80.4% for the month.</li><li>Total system capacity increased 3.7% to 1.26B available seat miles.</li><li>The carrier flew 1.13M passengers during the month.</li><li>The average stage length decreased 2.4% Y/Y to 841 miles.</li><li>Departures advanced 6.5% to 8,739.</li><li>The estimated average fuel cost per gallon during the month was $2.18 per gallon.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525569\" data-linked=\"Allegiant reports November traffic\" data-tweet=\"$ALGT - Allegiant reports November traffic https://seekingalpha.com/news/3525569-allegiant-reports-november-traffic?source=tweet\" data-url=\"https://seekingalpha.com/news/3525569-allegiant-reports-november-traffic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525563\" data-ts=\"1576080116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525563-microbot-medical-leads-healthcare-gainers-correvio-pharma-tops-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microbot Medical leads healthcare gainers; Correvio Pharma tops the losers</a></h4><ul><li><b>Gainers: </b>Microbot Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/MBOT' title='Microbot Medical Inc.'>MBOT</a>) <font color=\"green\">+29%</font>. Marinus Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals, Inc.'>MRNS</a>) <font color=\"green\">+27%</font>. Centogene (NASDAQ:<a href='https://seekingalpha.com/symbol/CNTG' title='Centogene N.V.'>CNTG</a>) <font color=\"green\">+18%</font>. Genetic Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/GENE' title='Genetic Technologies Limited'>GENE</a>) <font color=\"green\">+16%</font>. Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"green\">+14%</font>.</li><li><b>Losers: </b>Correvio Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CORV' title='Correvio Pharma Corp.'>CORV</a>) <font color=\"red\">-65%</font>. Iterum Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ITRM' title='Iterum Therapeutics plc'>ITRM</a>) <font color=\"red\">-36%</font>. Taronis Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/TRNX' title='Taronis Technologies, Inc.'>TRNX</a>) <font color=\"red\">-18%</font>. Madrigal Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a>) <font color=\"red\">-13%</font>. Momenta Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MNTA' title='Momenta Pharmaceuticals, Inc.'>MNTA</a>) <font color=\"red\">-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525563\" data-linked=\"Microbot Medical leads healthcare gainers; Correvio Pharma tops the losers\" data-tweet=\"$MBOT $MRNS $CNTG - Microbot Medical leads healthcare gainers; Correvio Pharma tops the losers https://seekingalpha.com/news/3525563-microbot-medical-leads-healthcare-gainers-correvio-pharma-tops-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525563-microbot-medical-leads-healthcare-gainers-correvio-pharma-tops-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525562\" data-ts=\"1576079894\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATXI\" target=\"_blank\">ATXI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525562-avenue-therapeutics-files-u-s-application-for-iv-tramadol-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avenue Therapeutics files U.S. application for IV tramadol; shares up 2%</a></h4><ul><li>Avenue Therapeutics (<a href='https://seekingalpha.com/symbol/ATXI' title='Avenue Therapeutics, Inc.'>ATXI</a> <font color=\"green\">+1.9%</font>) has <a href=\"https://seekingalpha.com/pr/17725108-avenue-therapeutics-announces-submission-of-new-drug-application-for-iv-tramadol\" target=\"_blank\">submitted </a>a marketing application to the FDA seeking approval of lead drug <a href=\"https://www.avenuetx.com/pipeline/\" target=\"_blank\">IV tramadol</a>, a dual-acting opioid, for the management of moderate-to-moderately severe pain in adults in a supervised healthcare setting.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525562\" data-linked=\"Avenue Therapeutics files U.S. application for IV tramadol; shares up 2%\" data-tweet=\"$ATXI - Avenue Therapeutics files U.S. application for IV tramadol; shares up 2% https://seekingalpha.com/news/3525562-avenue-therapeutics-files-u-s-application-for-iv-tramadol-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3525562-avenue-therapeutics-files-u-s-application-for-iv-tramadol-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525561\" data-ts=\"1576079854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNR\" target=\"_blank\">DNR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525561-denbury-resources-sees-17m-charge-for-employee-separation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Denbury Resources sees $17M charge for employee separation</a></h4><ul><li>Denbury Resources (<a href='https://seekingalpha.com/symbol/DNR' title='Denbury Resources Inc.'>DNR</a> <font color='green'>+0.9%</font>) <a href=\"https://www.sec.gov/ix?doc=/Archives/edgar/data/945764/000094576419000160/dnr-20191211x8kcorpora.htm\" target=\"_blank\">discloses</a> it has finalized the offering of a voluntary employee separation program as part of its cost-cutting efforts.</li><li>DNR estimates $17M in total VSP costs for one-time cash payments for severance and related costs, resulting in a pre-tax charge to Q4 earnings.</li><li>DNR expects $21M in ongoing annual savings associated with the workforce reduction.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525561\" data-linked=\"Denbury Resources sees $17M charge for employee separation\" data-tweet=\"$DNR - Denbury Resources sees $17M charge for employee separation https://seekingalpha.com/news/3525561-denbury-resources-sees-17m-charge-for-employee-separation?source=tweet\" data-url=\"https://seekingalpha.com/news/3525561-denbury-resources-sees-17m-charge-for-employee-separation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525558\" data-ts=\"1576079303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525558-local-broadcast-set-for-record-political-ad-season-guggenheim\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Local broadcast set for record political ad season - Guggenheim</a></h4><ul>   <li>\"All signs point to another record political cycle\" for local TV broadcasters, Guggenheim says in a bullish note looking to the 2020 race.</li>    <li>Recent updates from ad planning agencies indicate growth from election and Olympic spending, the firm's Curry Baker writes.</li>    <li>And political ads set to top $10B would be up about 15% from the $8.7B in the 2018 midterm political cycle.</li>    <li>Looking at the competitive markets, Baker says the best positioned local groups are Nexstar Media Group (<a href=\"http://seekingalpha.com/symbol/NXST\" target=\"_blank\">NXST</a> <font color=\"green\">+2.1%</font>), Gray Television (<a href=\"http://seekingalpha.com/symbol/GTN\" target=\"_blank\">GTN</a> <font color=\"green\">+1.9%</font>) and Sinclair Broadcast Group (<a href=\"http://seekingalpha.com/symbol/SBGI\" target=\"_blank\">SBGI</a> <font color=\"green\">+0.8%</font>), all of which he rates at Buy.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525558\" data-linked=\"Local broadcast set for record political ad season - Guggenheim\" data-tweet=\"$NXST $GTN $SBGI - Local broadcast set for record political ad season - Guggenheim https://seekingalpha.com/news/3525558-local-broadcast-set-for-record-political-ad-season-guggenheim?source=tweet\" data-url=\"https://seekingalpha.com/news/3525558-local-broadcast-set-for-record-political-ad-season-guggenheim\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525557\" data-ts=\"1576078934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KIDS\" target=\"_blank\">KIDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525557-orthopediatrics-up-3-after-pricing-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Orthopediatrics up 3% after pricing equity offering</a></h4><ul><li>Investors appear to like the <a href=\"https://seekingalpha.com/pr/17725317-orthopediatrics-corp-announces-pricing-of-offering-of-common-stock\" target=\"_blank\">pricing</a> of Orthopediatrics' (<a href='https://seekingalpha.com/symbol/KIDS' title='OrthoPediatrics Corp.'>KIDS</a> <font color=\"green\">+3%</font>) public offering of 1.57M common shares at $36.50 per share, 1.52M from the company and 50K from certain current investors.</li><li>Underwriters' over-allotment is an additional 235.5K shares. Closing date is December 13.</li><li>Yesterday's close was $38.57.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525557\" data-linked=\"Orthopediatrics up 3% after pricing equity offering\" data-tweet=\"$KIDS - Orthopediatrics up 3% after pricing equity offering https://seekingalpha.com/news/3525557-orthopediatrics-up-3-after-pricing-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3525557-orthopediatrics-up-3-after-pricing-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525556\" data-ts=\"1576078742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525556-senate-panel-takes-up-c-band-airwaves-auction-bill\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Senate panel takes up C-band airwaves auction bill</a></h4><ul>   <li>The Senate Commerce Committee is set to mark up the 5G Spectrum Act, and Height Capital observes that bill looks like the FCC's \"preferred\" route to a public auction of C-band frequencies.</li>    <li>A public auction has become the likelier outcome for the frequencies since FCC Commissioner Ajit Pai signaled support, against the wishes of C-Band alliance members like Intelsat (<a href=\"http://seekingalpha.com/symbol/I\" target=\"_blank\">I</a> <font color=\"green\">+4.1%</font>) and SES (<a href='https://seekingalpha.com/symbol/SGBAF' title='SES S.A.'>OTCPK:SGBAF</a>) that preferred a private auction.</li>    <li>The bill under consideration would allow the FCC to take 50% of gross proceeds from an auction, and Height notes that checks with Democratic staffers suggest if the bill directed the government's share to rural broadband, they'd give it a serious look.</li>    <li>Beneficiaries of new 5G spectrum: AT&amp;T (<a href=\"http://seekingalpha.com/symbol/T\" target=\"_blank\">T</a> <font color=\"green\">+0.3%</font>), Verizon (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color=\"red\">-0.1%</font>), T-Mobile (<a href=\"http://seekingalpha.com/symbol/TMUS\" target=\"_blank\">TMUS</a> <font color=\"red\">-0.1%</font>), Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color=\"red\">-0.5%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525556\" data-linked=\"Senate panel takes up C-band airwaves auction bill\" data-tweet=\"$SGBAF $I $T - Senate panel takes up C-band airwaves auction bill https://seekingalpha.com/news/3525556-senate-panel-takes-up-c-band-airwaves-auction-bill?source=tweet\" data-url=\"https://seekingalpha.com/news/3525556-senate-panel-takes-up-c-band-airwaves-auction-bill\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525551\" data-ts=\"1576078430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBIX\" target=\"_blank\">NBIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525551-aurelius-bearish-on-neurocrine-biosciences\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aurelius bearish on Neurocrine Biosciences</a></h4><ul><li>Investors appear relatively unmoved, at least so far, over a <a href=\"http://www.mavalue.org/research/nbix-the-tigers-stripes/?__cf_chl_jschl_tk__=e90df8c38d74f0c21fb8515b6577e45c0cef87c9-1576077571-0-AQwCB-aPdTGgpOV6Q2MBmnAiHW0KzwPpHvkjSrRRDwnLNcmutfQ5KMvYItrE6aeN4-b8qAi4SxVyGsLmjLtj4XDs10181Bpgbq2TX2V9_FB4sMY2eqqNVoANeUNud3Mhve0hWS_ECZjv58CydV_FKPB2tesK2B0W730du_lx1vDs9SW1yxp_KY_m3MM5QEvEhem3Ws27UySJ5kVwRDf07q0rISJAnyRb_jeHz3oFOqr792ap4CjjrlEIrY3IocAS1qNI8KUmRpYXtyWyKQ1u7Kgu1bz677R5Wfrb3Pg2ifFssVoIP953Ur42fCPhxTs0Bg\" target=\"_blank\">bearish report</a> on Neurocrine Biosciences (<a href='https://seekingalpha.com/symbol/NBIX' title='Neurocrine Biosciences, Inc.'>NBIX</a> <font color=\"red\">-0.6%</font>) from Marcus Aurelius Value, citing its alleged employment of a physician kickback scheme that sunk Otsuka Holdings' (<a href='https://seekingalpha.com/symbol/OTSKF' title='Otsuka Holdings Co., Ltd.'>OTCPK:OTSKF</a>) Avanir Pharmaceuticals which had to <a href=\"https://seekingalpha.com/news/3502143-avanir-to-pay-108m-over-nuedexta-kickback-scheme\" target=\"_blank\">pay $108M</a> to settle U.S. DOJ charges over its promotional activities for Nuedexta (dextromethorphan hydrobromide and quinidine sulfate).</li><li>The architect of Avanir's misbehavior is now the chief commercial officer at Neurocrine and is, allegedly, using the same approach to market Ingrezza (valbenazine), approved in the U.S. in April 2017 for tardive dyskinesia. The company is supposedly paying exorbitant speaking fees to the same doctors that Avanir did.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525551\" data-linked=\"Aurelius bearish on Neurocrine Biosciences\" data-tweet=\"$NBIX $OTSKF - Aurelius bearish on Neurocrine Biosciences https://seekingalpha.com/news/3525551-aurelius-bearish-on-neurocrine-biosciences?source=tweet\" data-url=\"https://seekingalpha.com/news/3525551-aurelius-bearish-on-neurocrine-biosciences\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525555\" data-ts=\"1576078352\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRVL\" target=\"_blank\">MRVL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525555-marvell-rises-rosenblatt-gains-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marvell rises as Rosenblatt gains confidence</a></h4><ul><li>Rosenblatt has increased confidence in Marvell's (NASDAQ:<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group Ltd.'>MRVL</a>) 5G infrastructure and strategic positioning.</li><li>Analyst Hans Mosesmann says competitors Broadcom and Intel aren't able to address critical tech in 5G base station silicon sockets.</li><li>Marvell's recent acquisition of Avera gives the company footing in remote radio units with application-specific IC capability.</li><li>MRVL shares are <font color=\"green\">up 4.1%</font> to $24.67. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/MRVL/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525555\" data-linked=\"Marvell rises as Rosenblatt gains confidence\" data-tweet=\"$MRVL - Marvell rises as Rosenblatt gains confidence https://seekingalpha.com/news/3525555-marvell-rises-rosenblatt-gains-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3525555-marvell-rises-rosenblatt-gains-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525554\" data-ts=\"1576078264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525554-crude-inventory-unexpectedly-rise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude inventory unexpectedly rise</a></h4><ul><li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>+0.8M</strong> barrels vs. -2.8M consensus, -4.9M last week.</li><li>Gasoline <strong>+5.4M</strong> barrels vs. +2.5M consensus, +3.4M last week.</li><li>Distillates<strong> +4.1M</strong> barrels vs. +1.6M consensus, +3.1M last week.</li><li>Futures <font color=\"red\">-0.14%</font> to $59.16.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P GSCI Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Trust II - ProShares Ultra Bloomberg Crude Oil'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='United States Brent Oil Fund, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='United States 12 Month Oil Fund, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525554\" data-linked=\"Crude inventory unexpectedly rise\" data-tweet=\"$USO $OIL $UCO - Crude inventory unexpectedly rise https://seekingalpha.com/news/3525554-crude-inventory-unexpectedly-rise?source=tweet\" data-url=\"https://seekingalpha.com/news/3525554-crude-inventory-unexpectedly-rise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>71&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525552\" data-ts=\"1576078189\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525552-aspen-group-rallies-11_7-post-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aspen Group rallies 11.7% post Q2 results</a></h4><ul><li>Aspen (<a href='https://seekingalpha.com/symbol/ASPU' title='Aspen Group, Inc.'>ASPU</a> <font color=\"green\">+11.7%</font>) reports <a href=\"https://seekingalpha.com/pr/17724339-aspen-group-reports-record-revenue-of-12_1-million-in-second-quarter-fiscal-year-2020\" target=\"_blank\">Q2</a> revenue increase of 49.3% Y/Y to $12.1M.</li><li>USU accounted for ~27% and Aspen University\u2019s Pre-Licensure BSN program accounted for ~12% of overall Company revenues.</li><li>Gross margin <font color=\"green\">increased 1,300 bps</font> to 63%, Aspen University margin represented 65%, while USU margin equalled 67%.</li><li>Aspen Group\u2019s new student enrollments increased 42% Y/Y to 2,217; Aspen University also increased 41% Y/Y to 1,823 and USU accounted for 394, up 45% Y/Y.</li><li>The bookings increased 92% Y/Y to $31.3M due to strong growth in highest LTV degree programs.</li><li>This translates to a 35% ARPU increase Y/Y to $14,125, driven by the company\u2019s focused marketing spending on the highest LTV degree programs during the quarter.</li><li>The company used cash of $0.3M for operations, an improvement of 84% Y/Y.</li><li>Adj. EBITDA was $1.36M as compared to an adj. EBITDA loss of $1.3M; Aspen University generated $2.6M of adj. EBITDA, while USU experienced an adj. EBITDA loss of $0.52M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525283-aspen-eps-beats-0_04-beats-on-revenue\" target=\"_blank\">Aspen EPS beats by $0.04, beats on revenue</a> (Dec. 10 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3525552\" data-linked=\"Aspen Group rallies 11.7% post Q2 results\" data-tweet=\"$ASPU - Aspen Group rallies 11.7% post Q2 results https://seekingalpha.com/news/3525552-aspen-group-rallies-11_7-post-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3525552-aspen-group-rallies-11_7-post-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525550\" data-ts=\"1576077810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525550-mongolian-government-approves-oyu-tolgoi-investment-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mongolian government approves Oyu Tolgoi investment agreement</a></h4><ul><li>Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto Group'>RIO</a> <font color=\"green\">+1.6%</font>) and Turquoise Hill Resources (<a href='https://seekingalpha.com/symbol/TRQ' title='Turquoise Hill Resources Ltd.'>TRQ</a> <font color=\"green\">+6.5%</font>) are rising after the Mongolia's parliament approves a resolution that instructs the  country's government to <a href=\"http://www.riotinto.com/media/media-releases-237_27949.aspx\" target=\"_blank\">improve the implementation</a> of the 2009 investment  agreement over the Oyu Tolgoi mine.</li><li>Rio says the passing of the resolution \"effectively  re-confirms the validity of all the investment agreements\" between the  Mongolian government, Rio and Turquoise Hill.</li><li>The resolution discusses exploring options  to look at the Mongolian government's equity share in Oyu Tolgoi, a  re-definition of the reserve report and updated feasibility report, and a  renewal of environmental and water assessments.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525550\" data-linked=\"Mongolian government approves Oyu Tolgoi investment agreement\" data-tweet=\"$RIO $TRQ - Mongolian government approves Oyu Tolgoi investment agreement https://seekingalpha.com/news/3525550-mongolian-government-approves-oyu-tolgoi-investment-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3525550-mongolian-government-approves-oyu-tolgoi-investment-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525543\" data-ts=\"1576077478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRNS\" target=\"_blank\">MRNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525543-marinus-prices-stock-offering-1_25-shares-up-33\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marinus prices stock offering at $1.25; shares up 33%</a></h4><ul><li>Nano cap Marinus Pharmaceuticals (<a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals, Inc.'>MRNS</a> <font color=\"green\">+32.6%</font>) is up on triple normal volume on the heels of its <a href=\"https://seekingalpha.com/pr/17725315-marinus-pharmaceuticals-announces-pricing-of-65-million-public-offering-of-common-stock-and\" target=\"_blank\">public offering</a> of 28M common shares at $1.25, apparently a more bullish price than investors were expecting (possibly aided by the convertible offering below).</li><li>Underwriters' over-allotment is an additional 4.2M shares. Closing date is December 13.</li><li>In a concurrent private placement, the company has agreed to sell $30M of convertible preferred stock convertible at $1.25 per common share.</li><li>Gross proceeds from both should be ~$65M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525543\" data-linked=\"Marinus prices stock offering at $1.25; shares up 33%\" data-tweet=\"$MRNS - Marinus prices stock offering at $1.25; shares up 33% https://seekingalpha.com/news/3525543-marinus-prices-stock-offering-1_25-shares-up-33?source=tweet\" data-url=\"https://seekingalpha.com/news/3525543-marinus-prices-stock-offering-1_25-shares-up-33\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525538\" data-ts=\"1576076916\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SKYS\" target=\"_blank\">SKYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525538-sky-solar-reports-1h-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sky Solar reports 1H results</a></h4><ul><li>Sky Solar (NASDAQ:<a href='https://seekingalpha.com/symbol/SKYS' title='Sky Solar Holdings, Ltd.'>SKYS</a>): 1H GAAP EPADS of -$0.26.</li><li>Revenue of $24.32M (-22.7% Y/Y)</li><li>Shares <font color=\"green\">+3%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17725482-sky-solar-holdings-ltd-reports-unaudited-financial-results-for-first-half-of-fiscal-year-2019\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3525538\" data-linked=\"Sky Solar reports 1H results\" data-tweet=\"$SKYS - Sky Solar reports 1H results https://seekingalpha.com/news/3525538-sky-solar-reports-1h-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3525538-sky-solar-reports-1h-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525537\" data-ts=\"1576076865\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OLN\" target=\"_blank\">OLN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525537-olin-to-shut-big-chlor-alkali-plant-year-end-2020\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Olin to shut big chlor alkali plant before year-end 2020</a></h4><ul><li>Olin Corp. (<a href='https://seekingalpha.com/symbol/OLN' title='Olin Corporation'>OLN</a> <font color='green'>+2.4%</font>) says it will <a href=\"https://seekingalpha.com/pr/17725156-olin-announces-facility-closures\" target=\"_blank\">permanently shut down</a> a Texas chlor alkali plant with a capacity of 230K tons before the end of next year, a move it expects will cut $35M from annual operating costs.</li><li>OLN says it plans to take $65M in related non-cash asset impairment charges in Q4.</li><li>The chemical products maker says it is taking \"necessary steps to reduce our annual fixed costs, align our production  capacity with the current needs of the marketplace and focus on the chlorine derivatives that generate the most value for the organization.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3525537\" data-linked=\"Olin to shut big chlor alkali plant before year-end 2020\" data-tweet=\"$OLN - Olin to shut big chlor alkali plant before year-end 2020 https://seekingalpha.com/news/3525537-olin-to-shut-big-chlor-alkali-plant-year-end-2020?source=tweet\" data-url=\"https://seekingalpha.com/news/3525537-olin-to-shut-big-chlor-alkali-plant-year-end-2020\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525536\" data-ts=\"1576076799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAGE\" target=\"_blank\">SAGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525536-sage-therapeutics-up-9-on-insider-buys\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sage Therapeutics up 9% on insider buys</a></h4><ul><li>Sage Therapeutics (<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics, Inc.'>SAGE</a> <font color=\"green\">+8.7%</font>) perks up on modestly higher volume on the heels of stock purchases by CEO Jeff Jonas (<a href=\"https://www.sec.gov/Archives/edgar/data/1042021/000156218019005990/xslF345X03/primarydocument.xml\" target=\"_blank\">7,500 shares</a>), CFO Kimi Iguchi (<a href=\"https://www.sec.gov/Archives/edgar/data/1304815/000156218019005993/xslF345X03/primarydocument.xml\" target=\"_blank\">20,000 shares</a> via stock option exercise) and CSO Albert Robichaud (<a href=\"https://www.sec.gov/Archives/edgar/data/1597553/000156218019005991/xslF345X03/primarydocument.xml\" target=\"_blank\">25,000 shares</a> purchased and 15,743 via option exercises).</li><li>Shares cratered <font color=\"red\">60%</font> on December 5 after the company announced that SAGE-217 <a href=\"https://seekingalpha.com/news/3523937-sage-therapeutics-sageminus-217-flunks-mdd-study-shares-down-53-premarket\" target=\"_blank\">failed to achieve</a> the primary objective in a late-stage depression study although the issue may have been non-compliance by certain participants.</li><li>The stock is <font color=\"green\">21%</font> since bottoming at $56.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525536\" data-linked=\"Sage Therapeutics up 9% on insider buys\" data-tweet=\"$SAGE - Sage Therapeutics up 9% on insider buys https://seekingalpha.com/news/3525536-sage-therapeutics-up-9-on-insider-buys?source=tweet\" data-url=\"https://seekingalpha.com/news/3525536-sage-therapeutics-up-9-on-insider-buys\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525534\" data-ts=\"1576076604\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRA\" target=\"_blank\">VRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525534-vera-bradleyminus-8-after-guidance-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vera Bradley -8% after guidance disappoints</a></h4><ul> <li>Shares of Vera Bradley (NASDAQ:<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley, Inc.'>VRA</a>) slide after the retailer issues sales guidance below expectations for the holiday quarter.</li> <li>Vera Bradley anticipates Q4 revenue of $155M to $162M vs. $162.5M consensus.</li><li>VRA <font color=\"red\">-8.15%</font> to $11.05 vs. the 52-week range of $7.94 to $14.51.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525463-vera-bradley-eps-beats-0_02-beats-on-revenue\" target=\"_blank\">Vera Bradley EPS beats by $0.02, beats on revenue</a> (Dec. 11)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3525534\" data-linked=\"Vera Bradley -8% after guidance disappoints\" data-tweet=\"$VRA - Vera Bradley -8% after guidance disappoints https://seekingalpha.com/news/3525534-vera-bradleyminus-8-after-guidance-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3525534-vera-bradleyminus-8-after-guidance-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525529\" data-ts=\"1576076124\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GMRE\" target=\"_blank\">GMRE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525529-global-medical-reit-sinks-7_9-after-upsized-stock-offering-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Medical REIT sinks 7.9% after upsized stock offering prices</a></h4><ul><li>Global Medical REIT (NYSE:<a href='https://seekingalpha.com/symbol/GMRE' title='Global Medical REIT Inc.'>GMRE</a>)<font color=\"red\"> slides 7.9% </font>after the REIT prices an upsized offering of 6M shares of common stock at $13.00 per share for gross proceeds of $78M.</li><li>Represents an 8.0% discount to GMRE's closing price of $14.13 on Tuesday.</li><li>Number of shares offered increases from 4.75M initially planned.</li><li>Grants greenshoe option for up to an additional 900,000 shares.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525344-global-medical-reit-launches-stock-offering\" target=\"_blank\">Global Medical REIT launches stock offering</a> (Dec. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3525529\" data-linked=\"Global Medical REIT sinks 7.9% after upsized stock offering prices\" data-tweet=\"$GMRE - Global Medical REIT sinks 7.9% after upsized stock offering prices https://seekingalpha.com/news/3525529-global-medical-reit-sinks-7_9-after-upsized-stock-offering-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3525529-global-medical-reit-sinks-7_9-after-upsized-stock-offering-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525522\" data-ts=\"1576075715\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TREE\" target=\"_blank\">TREE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525522-lendingtreeminus-6_8-on-light-2020-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LendingTree -6.8% on light 2020 guidance</a></h4><ul><li>LendingTree (NASDAQ:<a href='https://seekingalpha.com/symbol/TREE' title='LendingTree, Inc.'>TREE</a>)<font color=\"red\"> drops 6.8%</font> after its <a href=\"https://seekingalpha.com/pr/17725217-lendingtree-introduces-2020-guidance-ahead-of-investor-day\" target=\"_blank\">2020 revenue guidance</a> trails the consensus estimate.</li><li>Sees 2020 revenue of $1.25B-$1.30B vs. consensus of $1.31B.</li><li>Sees 2020 adjusted EBITDA of $225M-$235M</li><li>Sees variable marketing margin of $450M-$470M.</li><li><a href=\"https://investors.lendingtree.com/news-events/events-and-presentations\" target=\"_blank\">Investor Day presentation </a>at 10:30 AM ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525522\" data-linked=\"LendingTree -6.8% on light 2020 guidance\" data-tweet=\"$TREE - LendingTree -6.8% on light 2020 guidance https://seekingalpha.com/news/3525522-lendingtreeminus-6_8-on-light-2020-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3525522-lendingtreeminus-6_8-on-light-2020-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525500\" data-ts=\"1576073533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525500-gme-aeo-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GME, AEO among premarket losers</a></h4><ul><li>Correvio Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CORV' title='Correvio Pharma Corp.'>CORV</a>) <font color=\"red\">-59%</font> after FDA advisory committee <a href=\"https://seekingalpha.com/news/3525483-correvio-to-explore-strategic-alternatives-after-ad-com-snub-of-brinavess-for-af\" target=\"_blank\">thumbs down</a> on Brinavess.</li><li>Iterum Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ITRM' title='Iterum Therapeutics plc'>ITRM</a>) <font color=\"red\">-46%</font> after sulopenem <a href=\"https://seekingalpha.com/news/3525352-iterums-sulopenem-misses-endpoint-in-ciai-study-shares-down-48-after-hours\" target=\"_blank\">misses endpoint</a> in cIAI study.</li><li>GameStop (NYSE:<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a>) <font color=\"red\">-19%</font> on <a href=\"https://seekingalpha.com/news/3525291-gamestop-eps-misses-0_66-misses-on-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Aethlon Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a>) <font color=\"red\">-19%</font>.</li><li>The Children's Place (NASDAQ:<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place, Inc.'>PLCE</a>) <font color=\"red\">-16%</font> on <a href=\"https://seekingalpha.com/news/3525426-childrens-place-retail-stores-eps-beats-0_01-misses-on-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Technical Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"red\">-15%</font>.</li><li>Madrigal Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGL' title='Madrigal Pharmaceuticals, Inc.'>MDGL</a>) <font color=\"red\">-11%</font> on <a href=\"https://seekingalpha.com/news/3525410-madrigal-pharmaceuticals-prices-1_2m-share-offering\" target=\"_blank\">pricing</a> 1.2M-share offering.</li><li>United Natural Foods (NYSE:<a href='https://seekingalpha.com/symbol/UNFI' title='United Natural Foods, Inc.'>UNFI</a>) <font color=\"red\">-9%</font> on <a href=\"https://seekingalpha.com/news/3525430-united-natural-foods-eps-misses-0_15-beats-on-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li>American Eagle Outfitters (NYSE:<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/news/3525467-american-eagle-outfitters-eps-beats-0_01-beats-on-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Global Medical REIT (NYSE:<a href='https://seekingalpha.com/symbol/GMRE' title='Global Medical REIT Inc.'>GMRE</a>) <font color=\"red\">-8%</font> on <a href=\"https://seekingalpha.com/news/3525344-global-medical-reit-launches-stock-offering\" target=\"_blank\">announcing</a> stock offering.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525500\" data-linked=\"GME, AEO among premarket losers\" data-tweet=\"$CORV $ITRM $GME - GME, AEO among premarket losers https://seekingalpha.com/news/3525500-gme-aeo-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525500-gme-aeo-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525499\" data-ts=\"1576073477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525499-sbgl-olli-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SBGL, OLLI among premarket gainers</a></h4><ul><li>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"green\">+40%</font>.</li><li>My Size (NASDAQ:<a href='https://seekingalpha.com/symbol/MYSZ' title='My Size, Inc.'>MYSZ</a>) <font color=\"green\">+13%</font> on <a href=\"https://seekingalpha.com/pr/17725097-size-reports-significant-reduction-in-demoulins-measurement-related-costs-using-mysizeid\" target=\"_blank\">significantly reducing</a> DeMoulin's measurement-related costs, using MySizeID Widget.</li><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"green\">+12%</font> on <a href=\"https://seekingalpha.com/news/3525455-proteostasis-to-initiate-personalized-cf-study-in-europe-shares-up-17-premarket\" target=\"_blank\">initiating</a> personalized CF study in Europe.</li><li>CounterPath (NASDAQ:<a href='https://seekingalpha.com/symbol/CPAH' title='CounterPath Corporation'>CPAH</a>) <font color=\"green\">+11%</font> on <a href=\"https://seekingalpha.com/news/3525471-counterpath-reports-q2-results\" target=\"_blank\">Q2 results</a>.</li><li>Ollie's Bargain Outlet Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/OLLI' title='Ollie&#39;s Bargain Outlet Holdings, Inc.'>OLLI</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3525289-ollies-bargain-outlet-eps-beats-0_03-beats-on-revenue\" target=\"_blank\">Q3 results</a>.</li><li>Safe-T Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SFET' title='Safe-T Group Ltd'>SFET</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/pr/17724674-safe-t-signs-partner-agreement-fortune-500-affiliate-for-resale-of-sdp-solution\" target=\"_blank\">partner agreement</a> with a fortune 500 affiliate for the resale of its SDP Solution.</li><li>Wrap Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/WRTC' title='Wrap Technologies, Inc.'>WRTC</a>) <font color=\"green\">+9%</font>.</li><li>Photronics (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAB' title='Photronics, Inc.'>PLAB</a>) <font color=\"green\">+8%</font> after <a href=\"https://seekingalpha.com/news/3525415-photronics-eps-in-line-beats-on-revenue\" target=\"_blank\">Q4 results</a>.</li><li>Synlogic (NASDAQ:<a href='https://seekingalpha.com/symbol/SYBX' title='Synlogic, Inc.'>SYBX</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/news/3525493-synlogic-up-6-premarket-on-advancement-of-pku-candidate\" target=\"_blank\">advancement</a> of PKU candidate.</li><li>Kazia Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KZIA' title='Kazia Therapeutics Limited'>KZIA</a>) <font color=\"green\">+7%</font>.</li><li>Constellation Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNST' title='Constellation Pharmaceuticals, Inc.'>CNST</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/news/3525393-constellation-pharmaceuticals-prices-equity-offering\" target=\"_blank\">pricing</a> of equity offering.</li><li>LMP Automotive Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LMPX' title='LMP Automotive Holdings, Inc.'>LMPX</a>) <font color=\"green\">+6%</font>.</li><li>New Concept Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/GBR' title='New Concept Energy, Inc.'>GBR</a>) <font color=\"green\">+5%</font>.</li><li>Sibanye Gold (NYSE:<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye Gold Limited'>SBGL</a>) <font color=\"green\">+5% </font>as <a href=\"https://seekingalpha.com/news/3525488-south-african-gold-miners-gain-power-crisis-eases\" target=\"_blank\">power crisis eases</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525499\" data-linked=\"SBGL, OLLI among premarket gainers\" data-tweet=\"$CEI $MYSZ $PTI - SBGL, OLLI among premarket gainers https://seekingalpha.com/news/3525499-sbgl-olli-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3525499-sbgl-olli-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525488\" data-ts=\"1576073042\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBGL\" target=\"_blank\">SBGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525488-south-african-gold-miners-gain-power-crisis-eases\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">South African gold miners gain as power crisis eases</a></h4><ul><li><a href=\"https://www.bnnbloomberg.ca/south-africa-s-power-crisis-eases-after-eskom-rushes-to-fix-plants-1.1360873\" target=\"_blank\">The worst may be over</a> in South Africa's energy crisis after state power utility Eskom repaired broken plants and supplemented supply using gas turbines and pumped-storage facilities, Bloomberg reports.</li><li>Power cuts should be limited to 2K MW today - down from a peak of 6K MW on Monday  - and are expected to end next week, Eskom says.</li><li>Sibanye-Stillwater (NYSE:<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye Gold Limited'>SBGL</a>), Harmony  Gold (NYSE:<a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a>) and Impala Platinum (<a href='https://seekingalpha.com/symbol/IMPUY' title='Impala Platinum Holdings Limited'>OTCQX:IMPUY</a>) all were <a href=\"https://seekingalpha.com/news/3525113-severe-south-african-power-shortages-cut-mining-production\" target=\"_blank\">forced to cut  production since Monday</a> because of power shortages.</li><li>Eskom has struggled to meet demand for years, but the latest round of outages were caused by simultaneous breakdowns at several facilities and exacerbated by heavy rains that caused flooding and soaked coal stockpiles.</li><li>SBGL <font color=\"green\">+4.7%</font> and HMY <font color=\"green\">+3.2%</font> pre-market; Impala <font color=\"green\">+3.7%</font> in Johannesburg.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525488\" data-linked=\"South African gold miners gain as power crisis eases\" data-tweet=\"$SBGL $HMY $IMPUY - South African gold miners gain as power crisis eases https://seekingalpha.com/news/3525488-south-african-gold-miners-gain-power-crisis-eases?source=tweet\" data-url=\"https://seekingalpha.com/news/3525488-south-african-gold-miners-gain-power-crisis-eases\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525493\" data-ts=\"1576072256\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYBX\" target=\"_blank\">SYBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525493-synlogic-up-6-premarket-on-advancement-of-pku-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synlogic up 6% premarket on advancement of PKU candidate</a></h4><ul><li>Thinly traded nano cap Synlogic (NASDAQ:<a href='https://seekingalpha.com/symbol/SYBX' title='Synlogic, Inc.'>SYBX</a>) is up <font color=\"green\">6%</font> premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17724745-synlogic-bridging-study-data-solid-oral-formulation-of-synb1618-synthetic-biotic-approach-to\" target=\"_blank\">announcement </a>of positive results from a bridging study evaluating a solid formulation of SYNB1618 in healthy volunteers.</li><li>It says the safety and tolerability data support continued development for the potential treatment of phenylketonuria &#40;PKU&#41;. A Phase 2 study should launch in H1 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525493\" data-linked=\"Synlogic up 6% premarket on advancement of PKU candidate\" data-tweet=\"$SYBX - Synlogic up 6% premarket on advancement of PKU candidate https://seekingalpha.com/news/3525493-synlogic-up-6-premarket-on-advancement-of-pku-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3525493-synlogic-up-6-premarket-on-advancement-of-pku-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525483\" data-ts=\"1576071405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORV\" target=\"_blank\">CORV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525483-correvio-to-explore-strategic-alternatives-after-ad-com-snub-of-brinavess-for-af\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Correvio to explore strategic alternatives after Ad Com snub of Brinavess for AF</a></h4><ul> <li>Correvio Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CORV' title='Correvio Pharma Corp.'>CORV</a>) plans to explore <a href=\"https://seekingalpha.com/pr/17724972-correvio-announces-intention-to-explore-strategic-alternatives-to-maximize-stakeholder-value\" target=\"_blank\">strategic alternatives</a> after yesterday's <a href=\"https://seekingalpha.com/news/3525318-fda-advisory-committee-thumbs-down-on-correvios-brinavess-for-af\" target=\"_blank\">negative vote</a> from an FDA advisory committee on its application for Brinavess for the rapid conversion of recent onset atrial fibrillation in adults.</li>  <li>The Company is also taking steps to reduce operating costs outside the core European commercial business.</li><li>Shares down <font color=\"red\">57%</font> premarket on robust volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3525483\" data-linked=\"Correvio to explore strategic alternatives after Ad Com snub of Brinavess for AF\" data-tweet=\"$CORV - Correvio to explore strategic alternatives after Ad Com snub of Brinavess for AF https://seekingalpha.com/news/3525483-correvio-to-explore-strategic-alternatives-after-ad-com-snub-of-brinavess-for-af?source=tweet\" data-url=\"https://seekingalpha.com/news/3525483-correvio-to-explore-strategic-alternatives-after-ad-com-snub-of-brinavess-for-af\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525485\" data-ts=\"1576071147\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEO\" target=\"_blank\">AEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525485-american-eagle-outfittersminus-7-after-light-holiday-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Eagle Outfitters -7% after light holiday guidance</a></h4><ul> <li>American Eagle Outfitters (NYSE:<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a>) reports comparable sales rose 5% in Q3 vs. +3.4% consensus. A positive comp was delivered for both the store and digital channel.</li> <li>Comparable sales were up 2% for the American Eagle brand and 20% for Aerie.</li> <li>Gross profit margin fell 160 bps to 38.2% of sales on a higher level of markdowns.</li> <li>CEO update: \"We continued to deliver on our strategic pillars, with Aerie and American Eagle Jeans demonstrating strong sales and profit growth. Softer demand in certain AE apparel categories led to higher markdowns and has persisted into Q4. The team has been working hard to quickly course correct, and our focus is squarely on continuing to capitalize on the strength of our brands, accelerating the growth of Aerie, and creating shareholder value.\"</li> <li>Looking ahead, AEO expects Q4 comparable sales growth to be flat vs. +4.1% consensus and EPS of $0.34 to $0.36 vs. $0.46 consensus.</li> <li>Shares of AEO are <font color=\"red\">down 7.41%</font> premarket to $14.00.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525467-american-eagle-outfitters-eps-beats-0_01-beats-on-revenue\" target=\"_blank\">American Eagle Outfitters EPS beats by $0.01, beats on revenue</a> (Dec. 11)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525485\" data-linked=\"American Eagle Outfitters -7% after light holiday guidance\" data-tweet=\"$AEO - American Eagle Outfitters -7% after light holiday guidance https://seekingalpha.com/news/3525485-american-eagle-outfittersminus-7-after-light-holiday-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3525485-american-eagle-outfittersminus-7-after-light-holiday-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525475\" data-ts=\"1576070503\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LDOS\" target=\"_blank\">LDOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525475-leidos-wins-6_5b-u-s-defense-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leidos wins $6.5B U.S. defense contract</a></h4><ul><li>Leidos (NYSE:<a href='https://seekingalpha.com/symbol/LDOS' title='Leidos Holdings, Inc.'>LDOS</a>) <font color=\"green\">+1.6%</font> pre-market after it is <a href=\"https://www.govconwire.com/2019/12/leidos-wins-potential-65b-us-military-info-network-support-idiq/\" target=\"_blank\">awarded a potential 10-year, $6.5B contract</a> by the Defense Information Systems Agency operate and maintain a military telecommunications infrastructure.</li><li>The Global Solutions Management - Operations II award covers technical  support services for the Department of Defense Information Network and Defense Information  System Network starting Jan. 1, 2020, the Pentagon <a href=\"https://www.defense.gov/Newsroom/Contracts/Contract/Article/2037058/\" target=\"_blank\">announces</a>.</li><li>GSM-O II is a follow-on to the Global Information Grid Services Management-Operations contract originally held by the information systems and global solutions business Leidos acquired from Lockheed Martin.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525475\" data-linked=\"Leidos wins $6.5B U.S. defense contract\" data-tweet=\"$LDOS - Leidos wins $6.5B U.S. defense contract https://seekingalpha.com/news/3525475-leidos-wins-6_5b-u-s-defense-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3525475-leidos-wins-6_5b-u-s-defense-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525470\" data-ts=\"1576070297\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QGEN\" target=\"_blank\">QGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525470-qiagen-down-1-premarket-on-lack-of-siemens-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qiagen down 1% premarket on lack of Siemens interest</a></h4><ul><li>Reuters <a href=\"https://www.reuters.com/article/siemens-health-ma-qiagen/siemens-healthineers-says-has-no-interest-in-buying-qiagen-idUSL8N28L0R5\" target=\"_blank\">reports </a>that Siemens Healthineers has no interest in acquiring diagnostics outfit QIAGEN N.V. (NYSE:<a href='https://seekingalpha.com/symbol/QGEN' title='QIAGEN N.V.'>QGEN</a>). In an interview, CEO Bernd Montag said \"we are not looking for profitable niches, but for solutions for the large problems in the health sector.\"</li><li>Last month, shares jumped on unconfirmed <a href=\"https://seekingalpha.com/news/3518874-qiagen-up-7-on-rumored-thermo-fisher-interest\" target=\"_blank\">reports </a>that Thermo Fisher Scientific was mulling a bid.</li><li>Shares are down <font color=\"red\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525470\" data-linked=\"Qiagen down 1% premarket on lack of Siemens interest\" data-tweet=\"$QGEN $SIEGY $SMAWF - Qiagen down 1% premarket on lack of Siemens interest https://seekingalpha.com/news/3525470-qiagen-down-1-premarket-on-lack-of-siemens-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3525470-qiagen-down-1-premarket-on-lack-of-siemens-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525468\" data-ts=\"1576069959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACEL\" target=\"_blank\">ACEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525468-union-gaming-positive-on-accel-entertainment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Union Gaming positive on Accel Entertainment</a></h4><ul> <li>Union Gaming sees upside for Accel Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/ACEL' title='Accel Entertainment, Inc.'>ACEL</a>) in Q4 after it took terminal market share in Illinois during November.</li> <li>Looking further ahead, analyst John DeCree notes Missouri is closer to potentially approving gaming expansion, which could benefit Accel with more video gaming terminal business.</li> <li>Union Gaming has a Buy rating on Accel and price target of $13.00 vs. the 52-week trading range of $10.30 to $11.78.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525468\" data-linked=\"Union Gaming positive on Accel Entertainment\" data-tweet=\"$ACEL - Union Gaming positive on Accel Entertainment https://seekingalpha.com/news/3525468-union-gaming-positive-on-accel-entertainment?source=tweet\" data-url=\"https://seekingalpha.com/news/3525468-union-gaming-positive-on-accel-entertainment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525465\" data-ts=\"1576069656\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCG\" target=\"_blank\">PCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525465-pg-and-e-settlement-likely-end-to-bondholder-plan-and-zero-stock-price-citi-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PG&amp;E settlement likely end to bondholder plan and zero stock price, Citi says</a></h4><ul><li>PG&amp;E's (NYSE:<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a>) $13.5B settlement with wildfire victims <a href=\"https://thefly.com/thestreet/realmoney/index.php/PCGid3005093/PCG-Citi-boosts-PGE-target-to--says-no-chance-of-zero-stock-price-now\" target=\"_blank\">likely dealt a \"fatal blow\"</a> to the plan by bondholders led by Elliott Management to take over the company, as well as any scenario for a zero stock price, Citigroup's Praful Mehta says in raising his price target to $10.50/share from $5.</li><li>PCG shares have jumped 28% to $12.32 since <a href=\"https://seekingalpha.com/news/3524788-pg-and-e-jumps-to-two-month-high-on-13_5b-settlement\" target=\"_blank\">news of the settlement</a> and are indicated <font color=\"green\">+3.7%</font> pre-market.</li><li>The bondholder plan's primary leverage was its deal with the  Committee of Tort Claimants, and without that leverage, Mehta sees a \"very low likelihood\" of the bankruptcy judge rejecting the settlement and keeping the two competing plans alive.</li><li>Mehta, whose new $10.50 price target is based on the latest  settlement, still maintains a Sell rating on PG&amp;E.</li><li>PCG's average <a href=\"https://seekingalpha.com/symbol/PCG/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Neutral, while its <a href=\"https://seekingalpha.com/symbol/PCG/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> and <a href=\"https://seekingalpha.com/symbol/PCG/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525465\" data-linked=\"PG&amp;E settlement likely end to bondholder plan and zero stock price, Citi says\" data-tweet=\"$PCG - PG&amp;E settlement likely end to bondholder plan and zero stock price, Citi says https://seekingalpha.com/news/3525465-pg-and-e-settlement-likely-end-to-bondholder-plan-and-zero-stock-price-citi-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3525465-pg-and-e-settlement-likely-end-to-bondholder-plan-and-zero-stock-price-citi-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525464\" data-ts=\"1576069646\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVS\" target=\"_blank\">NVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525464-intec-pharma-down-14-premarket-on-novartis-exit-from-accordion-pill-agreement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intec Pharma down 14% premarket on Novartis exit from Accordion Pill agreement</a></h4><ul><li>Novartis (NYSE:<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a>) has <a href=\"https://seekingalpha.com/pr/17724879-intec-pharma-provides-update-on-novartis-feasibility-and-option-agreement\" target=\"_blank\">informed </a>Intec Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/NTEC' title='Intec Pharma Ltd.'>NTEC</a>) that it does not intend to exercise its option to develop a custom-designed Accordion Pill for one of its proprietary compounds, saying that the program no longer aligns with its strategic goals. It has agreed to pay Intec $1.5M as an exit fee.</li><li>Shares down <font color=\"red\">14%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525464\" data-linked=\"Intec Pharma down 14% premarket on Novartis exit from Accordion Pill agreement\" data-tweet=\"$NVS $NTEC - Intec Pharma down 14% premarket on Novartis exit from Accordion Pill agreement https://seekingalpha.com/news/3525464-intec-pharma-down-14-premarket-on-novartis-exit-from-accordion-pill-agreement?source=tweet\" data-url=\"https://seekingalpha.com/news/3525464-intec-pharma-down-14-premarket-on-novartis-exit-from-accordion-pill-agreement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525463\" data-ts=\"1576069567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRA\" target=\"_blank\">VRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525463-vera-bradley-eps-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vera Bradley EPS beats by $0.02, beats on revenue</a></h4><ul><li>Vera Bradley (NASDAQ:<a href='https://seekingalpha.com/symbol/VRA' title='Vera Bradley, Inc.'>VRA</a>): Q3 Non-GAAP EPS of $0.20 <font color=\"green\">beats by $0.02</font>; GAAP EPS of $0.00 <font color=\"red\">misses by $0.17</font>.</li><li>Revenue of $127.5M (+30.5% Y/Y) <font color=\"green\">beats by $3.16M</font>.</li><li>Shares <font color=\"green\">+3.91%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17724939-vera-bradley-announces-third-quarter-fiscal-2020-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3525463\" data-linked=\"Vera Bradley EPS beats by $0.02, beats on revenue\" data-tweet=\"$VRA - Vera Bradley EPS beats by $0.02, beats on revenue https://seekingalpha.com/news/3525463-vera-bradley-eps-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3525463-vera-bradley-eps-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525461\" data-ts=\"1576069496\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAY\" target=\"_blank\">PLAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525461-wells-fargo-unconvinced-on-dave-busters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo unconvinced on Dave &amp; Buster&#39;s</a></h4><ul> <li>Wells Fargo updates on Dave &amp; Buster's Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a>) following the company's <a href=\"https://seekingalpha.com/news/3525317-dave-bustersplus-3-after-guidance-satisfies\" target=\"_blank\">Q3</a> earnings report.</li> <li>\"We're not yet willing to recommend investors build positions in the name, as the underlying business fundamentals remain challenged (i.e., negative SSS, continued entrance of new competitors in the category and margin contraction) and given our view that expectations for 2020 and beyond may need to move lower as the company potentially pulls more aggressive sales-driving levers at the expense of above-industry store margins,\" writes analyst Jon Tower.</li> <li>\"Given the current sales weakness, limited visibility into improvement and our growing belief that margins may need to be reset lower, we view the risk-reward as balanced at current levels,\" he adds.</li> <li>Wells keeps a price target of $42 on PLAY vs. the sell-side average PT of $44.93.</li> <li>PLAY is <font color=\"green\">up 1.90%</font> premarket after its earnings beat.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525461\" data-linked=\"Wells Fargo unconvinced on Dave &amp; Buster&#39;s\" data-tweet=\"$PLAY - Wells Fargo unconvinced on Dave &amp; Buster&#39;s https://seekingalpha.com/news/3525461-wells-fargo-unconvinced-on-dave-busters?source=tweet\" data-url=\"https://seekingalpha.com/news/3525461-wells-fargo-unconvinced-on-dave-busters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525455\" data-ts=\"1576069139\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525455-proteostasis-to-initiate-personalized-cf-study-in-europe-shares-up-17-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteostasis to initiate personalized CF study in Europe; shares up 17% premarket</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <a href=\"https://seekingalpha.com/pr/17724850-proteostasis-therapeutics-to-initiate-first-ever-personalized-medicine-based-clinical-trial\" target=\"_blank\">announces</a> positive, initial ex-vivo results of its proprietary cystic fibrosis transmembrane conductance regulator &#40;CFTR&#41; modulators, PTI-801, PTI-808, and PTI-428, in individuals with cystic fibrosis &#40;CF&#41; who are ineligible for the current standard of care due to their genotype.</li><li>The data are part of a pan-European strategic initiative, known as HIT-CF (Human Individualized Therapy of CF), which seeks to accelerate the development of personalized therapies for CF patients, for whom no currently approved CFTR modulator therapy is indicated.</li> <li>HIT-CF collects tissue samples and develops organoids, or miniaturized organs, that are genetically identical to the patient donor, and share the same micro-anatomy as the organ from which they were derived.</li> <li>Thus far, rectal organoids from over 300 subjects have been collected for functional profiling and of those, 65 have been tested for response to PTI's investigational drugs.</li><li>Early results support the initiation of enrollment of responding subjects into HIT-CF's clinical trial known as \"CHOICES\" (Crossover trial based on Human Organoid Individual response in CF - Efficacy Study), which is designed to evaluate the translation of organoid ex-vivo response to potential clinical benefit, such as changes in FEV<sub>1</sub> and sweat chloride.</li><li>CHOICES should launch in mid-2020 with initial data expected by year-end.</li><li>Results from the HIT-CF project to date will be presented at the Keystone Symposia on Tissue Organoids taking place on January 19-23, 2020 in Vancouver, BC, Canada.</li><li>Shares up <font color=\"green\">17%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525455\" data-linked=\"Proteostasis to initiate personalized CF study in Europe; shares up 17% premarket\" data-tweet=\"$PTI - Proteostasis to initiate personalized CF study in Europe; shares up 17% premarket https://seekingalpha.com/news/3525455-proteostasis-to-initiate-personalized-cf-study-in-europe-shares-up-17-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3525455-proteostasis-to-initiate-personalized-cf-study-in-europe-shares-up-17-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525452\" data-ts=\"1576068394\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBLU\" target=\"_blank\">JBLU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525452-jetblue-airways-reports-november-traffic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JetBlue Airways reports November traffic</a></h4><ul> <li>JetBlue (NASDAQ:<a href='https://seekingalpha.com/symbol/JBLU' title='JetBlue Airways Corporation'>JBLU</a>) <a href=\"https://seekingalpha.com/pr/17724810-jetblue-airways-reports-november-traffic\" sasource=\"qp_sum_news_5\" target=\"_blank\">reports</a> revenue passenger miles rose 3.7% to 4.26B in November.</li><li>Capacity expanded 7.1% to 5.27B available seat miles.</li><li>Passengers flown +0.4% to 3.4M.</li><li>Load factor declined 270 bps to 80.8%.</li><li>YTD load factor down 110 bps to 84.1%.</li><li>Departures grew 1.3% during the month and average stage length advanced 3.3% to 1,138 miles.</li><li>Q4 revenue per available seat mile is expected to range between -3.5% to -1.5%.</li><li>JBLU <font color=\"red\">-2.12%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525452\" data-linked=\"JetBlue Airways reports November traffic\" data-tweet=\"$JBLU - JetBlue Airways reports November traffic https://seekingalpha.com/news/3525452-jetblue-airways-reports-november-traffic?source=tweet\" data-url=\"https://seekingalpha.com/news/3525452-jetblue-airways-reports-november-traffic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525446\" data-ts=\"1576067664\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAB\" target=\"_blank\">PLAB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525446-photronicsplus-7_4-after-revenue-beat-upside-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Photronics +7.4% after revenue beat, upside outlook</a></h4><ul><li>Photronics (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAB' title='Photronics, Inc.'>PLAB</a>)<a href=\"https://seekingalpha.com/news/3525415-photronics-eps-in-line-beats-on-revenue\" target=\"_blank\"> in-line Q4 earnings</a> with upside revenue. The upside Q1 outlook sees revenue of $146-154M and EPS of $0.13-0.48.</li><li>Q4 integrated circuit revenue was up 12% sequentially and 1% Y/Y to $112.5M. Flat panel display sales are up 15% Q/Q and 29% Y/Y to $43.7M.</li><li>Cash from operating activities totaled $48.3M, resulting in a $206.5M cash balance.</li><li>Earnings call starts at 8:30 AM with a webcast <a href=\"https://www.globenewswire.com/Tracker?data=S26gid0icrYd8alZApAj_L7tGmjeh0s9maCCFr2Y0Ny0yhuTtHCZXST4k_FtwOwaqs9n8M5EanGVYInqre2tdHe9h3eEk7kuufJmmD2BUqI=\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17724755-photronics-reports-fourth-quarter-fiscal-2019-results\" target=\"_blank\">Press release</a>.</li><li>PLAB shares are <font color=\"green\">up 7.4%</font> pre-market to $13.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525446\" data-linked=\"Photronics +7.4% after revenue beat, upside outlook\" data-tweet=\"$PLAB - Photronics +7.4% after revenue beat, upside outlook https://seekingalpha.com/news/3525446-photronicsplus-7_4-after-revenue-beat-upside-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3525446-photronicsplus-7_4-after-revenue-beat-upside-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525443\" data-ts=\"1576067478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNFI\" target=\"_blank\">UNFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525443-united-natural-foodsminus-8-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Natural Foods -8% after earnings</a></h4><ul> <li>United Natural Foods (NYSE:<a href='https://seekingalpha.com/symbol/UNFI' title='United Natural Foods, Inc.'>UNFI</a>) slides after <a href=\"https://seekingalpha.com/pr/17724829-united-natural-foods-inc-reports-first-quarter-fiscal-2020-results\" target=\"_blank\">FQ1</a> results disappoint following the integration of Supervalu.</li> <li>The company reports adjusted EBITDA was $121.7M vs. $135.2M consensus and $86.2M a year ago.</li> <li>Gross margin fell to 12.8% of sales from 14.4% a year ago. The drop was primarily due to the addition of the Supervalu business at a low margin profile.</li> <li>The company says outstanding debt increased due to an increase in working capital to support the holiday selling period.  The increase in working capital is expected to reverse by the end of the FQ2.</li><li>Looking ahead, United Natural Foods sees full-year revenue of $23.5B to $24.3B vs. $23.9B consensus and EPS of $1.22 to $1.76 vs. $1.28 consensus.</li> <li>Shares of UNFI are <font color=\"red\">down 8.31%</font> in premarket action to $9.05.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525430-united-natural-foods-eps-misses-0_15-beats-on-revenue\" target=\"_blank\">United Natural Foods EPS misses by $0.15, beats on revenue</a> (Dec. 11)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3525443\" data-linked=\"United Natural Foods -8% after earnings\" data-tweet=\"$UNFI - United Natural Foods -8% after earnings https://seekingalpha.com/news/3525443-united-natural-foodsminus-8-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3525443-united-natural-foodsminus-8-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3525441\" data-ts=\"1576066987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AHCO\" target=\"_blank\">AHCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3525441-wells-cuts-view-on-cigna-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells cuts view on Cigna in premarket analyst action</a></h4><ul><li>AdaptHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/AHCO' title='AdaptHealth Corp.'>AHCO</a>) initiated with Outperform rating and $13 (30% upside) price target at SVB Leerink.</li><li>Cyclo Therapeutics (<a href='https://seekingalpha.com/symbol/CTDH' title='Cyclo Therapeutics, Inc.'>OTCQB:CTDH</a>) initiated with Buy rating and $1.25 (400% upside) price target at ThinkEquity.</li><li>CryoLife (NYSE:<a href='https://seekingalpha.com/symbol/CRY' title='CryoLife, Inc.'>CRY</a>) upgraded to Buy at Needham. Shares up <font color=\"green\">2% </font>premarket.</li><li>Acadia Healthcare (NASDAQ:<a href='https://seekingalpha.com/symbol/ACHC' title='Acadia Healthcare Company, Inc.'>ACHC</a>) downgraded to Equal Weight with a $35 (9% upside) price target at Wells Fargo.</li><li>Cigna (NYSE:<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a>) downgraded to Underweight with a $181 (6% downside risk) price target at Wells Fargo.</li><li>Correvio Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CORV' title='Correvio Pharma Corp.'>CORV</a>) downgraded to Sell at Bloom Burton &amp; Co. Shares down <font color=\"red\">59%</font> premarket after negative FDA advisory committee vote on Brinavess for AF.</li><li>DENTSPLY SIRONA (NASDAQ:<a href='https://seekingalpha.com/symbol/XRAY' title='DENTSPLY SIRONA Inc.'>XRAY</a>) downgraded to Neutral with a $65 (13% upside) price target at JPMorgan. Shares down <font color=\"red\">2%</font> premarket.</li><li>Encompass Health (NYSE:<a href='https://seekingalpha.com/symbol/EHC' title='Encompass Health Corporation'>EHC</a>) downgraded to Underweight with a $68 (5% downside risk) price target at Wells Fargo.</li><li>GenMark Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/GNMK' title='GenMark Diagnostics, Inc.'>GNMK</a>) downgraded to Neutral with a $7 (25% upside) price target at JPMorgan.</li><li>Iterum Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ITRM' title='Iterum Therapeutics plc'>ITRM</a>) downgraded to Market Perform with a $4 (18% downside risk) price target at SVB Leerink. Shares down <font color=\"red\">47%</font> premarket after failed Phase 3 study of sulopenem.</li><li>Lexicon Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a>) downgraded to Hold at Gabelli &amp; Co. Shares down <font color=\"red\">2%</font> premarket.</li><li>Surmodics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRDX' title='Surmodics, Inc.'>SRDX</a>) downgraded to Hold at Needham. Shares down <font color=\"red\">2%</font> premarket.</li><li>Walgreens Boots Alliance (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>) downgraded to Equal Weight with a $61 (4% upside) price target at Wells Fargo. Shares down <font color=\"red\">1%</font> premarket.</li><li>WellCare Health Plans (NYSE:<a href='https://seekingalpha.com/symbol/WCG' title='WellCare Health Plans, Inc.'>WCG</a>) downgraded to Equal Weight with a $342 (7% upside) price target at Wells Fargo.</li></ul><div class=\"tiny-share-widget\" data-id=\"3525441\" data-linked=\"Wells cuts view on Cigna in premarket analyst action\" data-tweet=\"$AHCO $CRY $ACHC - Wells cuts view on Cigna in premarket analyst action https://seekingalpha.com/news/3525441-wells-cuts-view-on-cigna-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3525441-wells-cuts-view-on-cigna-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}